var title_f31_13_31952="Resectoscope parts";
var content_f31_13_31952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysteroscopy: Resectoscope parts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Linda D Bradley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31952=[""].join("\n");
var outline_f31_13_31952=null;
var title_f31_13_31953="Detached retina PI";
var content_f31_13_31953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F84036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F84036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Detached retina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The retina is the tissue at the back of the eye. If it gets a tear or hole, it can start to come off the back of the eye. This causes vision changes. It can cause vision loss or even blindness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31953=[""].join("\n");
var outline_f31_13_31953=null;
var title_f31_13_31954="Interstitial keratitis in congenital syphilis";
var content_f31_13_31954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital syphilis: Interstitial keratitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows a stromal haze in both eyes of this child due to interstitial keratitis, a manifestation of late congenital syphilis. Interstitial keratitis is an inflammation of the connective tissue structure of the cornea. It usually is bilateral.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: the Public Health Image Library, Centers for Disease Control and Prevention. Photo by Susan Lindsley.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31954=[""].join("\n");
var outline_f31_13_31954=null;
var title_f31_13_31955="Cap polyposis Endosc I";
var content_f31_13_31955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Cap polyposis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Colonoscopy showing multiple erythematous polyps with an overlying white exudate typical of cap polyposis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome D Waye, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31955=[""].join("\n");
var outline_f31_13_31955=null;
var title_f31_13_31956="Clinical trials of HIV antiretroviral therapy: Agents in advanced stages of development";
var content_f31_13_31956=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials of HIV antiretroviral therapy: Agents in advanced stages of development",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/13/31956/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31956/contributors\">",
"     Paul E Sax, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/13/31956/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31956/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/13/31956/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31956/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/13/31956/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several antiretroviral agents are in advanced stages of development for the treatment of HIV infection. However, the pace of drug development has recently slowed due to high levels of success of currently approved drugs. This topic is devoted to clinical trials of agents in the late stage of development.",
"   </p>",
"   <p>",
"    Information regarding agents that are currently available by prescription can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32918?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTEGRASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-1 integrase is essential for viral replication; integrase inserts viral DNA into the cellular genome through two catalytic reactions. Loss of integrase activity disrupts the viral life cycle.",
"   </p>",
"   <p>",
"    The two clinically available drugs from this class,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    and elvitegravir, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95177256\">",
"    <span class=\"h2\">",
"     Dolutegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dolutegravir is an HIV integrase inhibitor that appears to have high virologic efficacy and good tolerability in clinical trials of treatment-na&iuml;ve patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31956/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, it has activity against some",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    - and elvitegravir-resistant viruses.",
"   </p>",
"   <p>",
"    In a placebo-controlled trial of 833 treatment-na&iuml;ve patients, viral suppression to &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at 48 weeks was achieved more frequently among those randomly assigned to receive 50 mg dolutegravir with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    daily versus single-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    daily (88 versus 81 percent, 95% CI of difference 2.5-12.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31956/abstract/2\">",
"     2",
"    </a>",
"    ]. The median time to virologic suppression was faster (28 versus 84 days) and the absolute change in CD4 cell count from baseline to 48 weeks was higher (267 versus 208",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    with the dolutegravir versus efavirenz-based regimen. Additional findings from this study include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rates of virologic failure were similar between the two groups (4 percent in both). Among patients with virologic failure who were able to undergo genotypic testing, no nucleoside reverse transcriptase inhibitor (NRTI) or integrase inhibitor resistance mutations were detected in those receiving the dolutegravir-based regimen, whereas one NRTI and four non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations were detected in those receiving the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      -based regimen.",
"     </li>",
"     <li>",
"      Adverse events leading to regimen discontinuation were less common with dolutegravir (2 versus 10 percent). Otherwise, adverse events overall were similarly common with both regimens. Insomnia was more common with the dolutegravir-based regimen, whereas dizziness, abnormal dreams, and rash were more common with the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      -based regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An earlier, smaller trial of various doses of dolutegravir (10, 25, or 50 mg daily) versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , either with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    , had comparable findings, with similar efficacy observed for the various doses of dolutegravir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31956/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dolutegravir-based regimens also compare favorably to those that contain",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , another integrase inhibitor. In a trial of 827 treatment-na&iuml;ve patients randomly assigned to receive 50 mg dolutegravir daily or 400 mg raltegravir twice daily, in addition to an investigator-selected NRTI background of either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    , rates of viral suppression to &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at 48 weeks were noninferior for the dolutegravir-based regimens compared with the raltegravir-based regimens (88 versus 85 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31956/abstract/3\">",
"     3",
"    </a>",
"    ]. Among patients with baseline HIV RNA &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    the response rates were also comparable (82 and 75 percent for dolutegravir and raltegravir, respectively). There was no difference in rates of discontinuation for adverse events. No integrase or NRTI resistance mutations were detected among patients with virologic failure on a dolutegravir-based regimen.",
"   </p>",
"   <p>",
"    These data suggest that once-daily dosing of dolutegravir is effective in treatment-na&iuml;ve HIV-infected patients, without the need for pharmacokinetic boosting, when given in combination with two nucleoside analogs.",
"   </p>",
"   <p>",
"    Additionally, data from small prospective clinical trials suggest that dolutegravir dosed twice daily combined with an optimized baseline regimen that contains at least one other active agent is effective in some treatment-experienced patients who harbor virus with mutations conferring resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    or elvitegravir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31956/abstract/4\">",
"     4",
"    </a>",
"    ]. The activity profile of dolutegravir in the presence of various raltegravir or elvitegravir resistance mutations has been further characterized and underscores the importance of genotype resistance testing in patients who are failing regimens containing these first-generation integrase inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31956/abstract/5\">",
"     5",
"    </a>",
"    ].&nbsp;",
"   </p>",
"   <p>",
"    Although small increases in creatinine were observed among HIV-infected patients taking dolutegravir in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31956/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], a pharmacological study in healthy volunteers suggested that these changes are due to blockade of creatinine secretion without effect on actual glomerular filtration rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31956/abstract/6\">",
"     6",
"    </a>",
"    ]. Studies in healthy volunteers also suggest that dolutegravir may be taken with or without food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31956/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19490982\">",
"    <span class=\"h1\">",
"     BOOSTING AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacokinetic boosting agents are included in a regimen not for direct antiretroviral activity but to improve the trough serum concentration of the coadministered antiretroviral agent(s). The concept of pharmacokinetic boosting is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link&amp;anchor=H32#H32\">",
"     \"HIV protease inhibitors\", section on 'Pharmacokinetic boosting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19491005\">",
"    <span class=\"h2\">",
"     Cobicistat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cobicistat is a pharmacokinetic booster that inhibits cytochrome p450 enzyme cyp3A4. Chemically similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , it has no antiviral activity and greater solubility, which more easily allows coformulation with other agents. Cobicistat is already available in a single combination pill with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , and elvitegravir (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=see_link&amp;anchor=H4926570#H4926570\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\", section on 'Treatment-naive patients'",
"    </a>",
"    ). In a phase III double blind trial of 700 treatment-naive patients who also received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , cobicistat was noninferior to ritonavir, with similar rates of virologic suppression and adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31956/abstract/8\">",
"     8",
"    </a>",
"    ]. Coformulations of cobicistat with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    and atazanavir are in development, and a one-pill regimen of darunavir, cobicistat, emtricitabine, and the tenofovir pro-drug tenofovir&nbsp;alafenamide is also in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CCR5 ANTAGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV enters CD4+ T-cells via the chemokine receptor 5 (CCR5) or CXC chemokine receptor 4 (CXCR4 coreceptor). Viral strains from patients with early stage disease usually use CCR5 coreceptors, whereas approximately one-half of viral strains from patients with advanced immunosuppression enter via either the CXCR4 coreceptor alone, or both the CCR5 and the CXCR4 receptors",
"    <span class=\"nowrap\">",
"     (\"dual/mixed\"",
"    </span>",
"    tropic viruses).",
"   </p>",
"   <p>",
"    Because CCR5 antagonists are not active against CXCR4 or",
"    <span class=\"nowrap\">",
"     dual/mixed",
"    </span>",
"    tropic viruses, a pretreatment screening test has been utilized in study protocols to assess viral tropism. This tropism test is similar to an HIV resistance phenotype, and can determine whether a response from a CCR5 antagonist should be expected. Genotypic tropism tests are also available that offer similar information at a lower cost.",
"   </p>",
"   <p>",
"    The first drug in this class,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , was approved for use in 2007. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32918?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\"",
"    </a>",
"    .) Although vicriviroc was studied in phase III clinical trials, the developers elected not to file for approval at least in part due to the excellent existing available HIV treatments and a clinical trial demonstrating no additional benefit of vicriviroc over placebo in treatment-experienced patients. Cenicriviroc, another investigational CCR5 antagonist, additionally blocks the CCR2 receptor, which has a role in metabolic and inflammatory pathways. The drug is currently being studied in Phase II clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CXCR4 ANTAGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, HIV enters CD4+ T-cells via the chemokine receptor 5 (CCR5) or CXC chemokine receptor 4 (CXCR4 coreceptor). Viral strains from patients with early stage disease use CCR5 coreceptors exclusively, whereas approximately one-half of viral strains from patients with advanced immunosuppression enter via either the CXCR4 coreceptor alone, or both the CCR5 and the CXCR4 receptors",
"    <span class=\"nowrap\">",
"     (\"dual/mixed\"",
"    </span>",
"    tropic viruses).",
"   </p>",
"   <p>",
"    One study has demonstrated that there are two distinct types of dual-tropic viruses based on their ability to use different coreceptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31956/abstract/9\">",
"     9",
"    </a>",
"    ]. The preferential use of CCR5 (\"dual-R\") or the ability to utilize both coreceptors equally (dual-X) could potentially affect the efficacy of CCR5 and CXCR4 coreceptor inhibitors.",
"   </p>",
"   <p>",
"    Although CXCR4 antagonism is an attractive antiviral target, particularly in treatment-experienced patients, development of agents that bind and inhibit this receptor has been hampered by associated toxicities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31956/abstract/10\">",
"     10",
"    </a>",
"    ]. Whether the toxicities are a direct result of CXCR4 inhibition is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dolutegravir, an HIV integrase inhibitor, in combination with two nucleoside analogs, is associated with high rates of HIV RNA suppression over 48 weeks in treatment-na&iuml;ve patients and is favorably comparable to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      -based regimens. Once-daily dosing is effective in this population without the need for pharmacokinetic boosting and has an acceptable side effect profile. It also has activity against some raltegravir- and elvitegravir-resistant viruses when dosed twice daily in treatment-experienced patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Integrase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cobicistat is a pharmacokinetic booster that has no antiviral activity but can be easily coformulated with other agents. It is noninferior to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      when combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      for treatment-na&iuml;ve patients and is associated with similar rates of adverse effects. Other combinations and coformulations are being developed and studied. (See",
"      <a class=\"local\" href=\"#H19491005\">",
"       'Cobicistat'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31956/abstract/1\">",
"      van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12:111.",
"     </a>",
"    </li>",
"    <li>",
"     Walmsley S, Antela A, Clumeck N, et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results - SINGLE (ING114467). Presented at the 52nd annual  Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Sept 9-12, 2012, #H-556b.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31956/abstract/3\">",
"      Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381:735.",
"     </a>",
"    </li>",
"    <li>",
"     Soriano V, Cox J, Eron J, et al. Dolutegravir (DTG, S/GSK1349572) treatment of HIV subjects with raltegravir resistance: viral suppression at week 24 in the VIKING study. Presented at the 13th annual European AIDS conference, Oct 12-15, 2011, Belgrade, Serbia,",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31956/abstract/5\">",
"      Underwood MR, Johns BA, Sato A, et al. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr 2012; 61:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31956/abstract/6\">",
"      Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 2013; 75:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31956/abstract/7\">",
"      Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2012; 56:1627.",
"     </a>",
"    </li>",
"    <li>",
"     Gallant J, et al. 19th IAC; Washington, DC; July 22-27, 2012; Abstract TUAB0103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31956/abstract/9\">",
"      Huang W, Eshleman SH, Toma J, et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 2007; 81:7885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31956/abstract/10\">",
"      Kuritzkes DR. HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS 2009; 4:82.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3787 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31956=[""].join("\n");
var outline_f31_13_31956=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTEGRASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95177256\">",
"      Dolutegravir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19490982\">",
"      BOOSTING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19491005\">",
"      Cobicistat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CCR5 ANTAGONISTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CXCR4 ANTAGONISTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32918?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_13_31957="Desmopressin: Patient drug information";
var content_f31_13_31957=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Desmopressin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     see \"Desmopressin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/45/15062?source=see_link\">",
"     see \"Desmopressin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DDAVP&reg;;",
"     </li>",
"     <li>",
"      Stimate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Desmopressin&reg;;",
"     </li>",
"     <li>",
"      DDAVP&reg;;",
"     </li>",
"     <li>",
"      DDAVP&reg; Melt;",
"     </li>",
"     <li>",
"      Minirin&reg;;",
"     </li>",
"     <li>",
"      Novo-Desmopressin;",
"     </li>",
"     <li>",
"      Octostim&reg;;",
"     </li>",
"     <li>",
"      PMS-Desmopressin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop bedwetting in children.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower urine output.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hemophilia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat von Willebrand disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701910",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to desmopressin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703787",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Low sodium levels or very bad kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what the doctor said about how much liquid to drink and how much to work out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695853",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime for bedwetting.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694867",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what doctor says for drinking liquids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nose:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use solution and spray in the nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695979",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, under the skin, or into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nose:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699377",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store DDAVP&reg; and Stimate&reg; at room temperature. Keep upright. Throw away any part not used after 6 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699379",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store DDAVP&reg; Rhinal Tube and Minirin&trade; in a refrigerator or at room temperature. If stored at room temperature, throw away any part not used after 3 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12361 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31957=[""].join("\n");
var outline_f31_13_31957=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157823\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157824\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012034\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012033\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012038\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012039\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012041\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012036\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012037\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012042\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012043\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=related_link\">",
"      Desmopressin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/45/15062?source=related_link\">",
"      Desmopressin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_13_31958="Eprosartan: Drug information";
var content_f31_13_31958=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Eprosartan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/34/6693?source=see_link\">",
"    see \"Eprosartan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Teveten&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Teveten&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F165953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F165926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension: Oral: Dosage must be individualized. Can administer once or twice daily with total daily doses of 400-800 mg. Usual starting dose is 600 mg once daily as monotherapy in patients who are euvolemic. Limited clinical experience with doses &gt;800 mg.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F165927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F165928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate-to-severe impairment: No initial starting dosage adjustment is necessary; however, carefully monitor the patient. Maximum dose: 600 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Poorly removed (Cl",
"     <sub>",
"      HD",
"     </sub>",
"     &lt;1 L/hour)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F165929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No starting dosage adjustment is necessary; however, carefully monitor the patient.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Teveten&reg;: 400 mg, 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F165904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension; may be used alone or in combination with other antihypertensives",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F165951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (2%), depression (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypertriglyceridemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (8%), rhinitis (4%), pharyngitis (4%), cough (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (2%), injury (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal ECG, angina, arthritis, asthma, ataxia, bradycardia, BUN increased, creatinine increased, eczema, edema, esophagitis, ethanol intolerance, gingivitis, gout, hypotension, influenza-like symptoms, leg cramps, leukopenia, maculopapular rash, migraine, neuritis, neutropenia, orthostasis, palpitation, paresthesia, peripheral ischemia, purpura, renal calculus, somnolence, tachycardia, tendonitis, thrombocytopenia, tinnitus, tremor, urinary incontinence, vertigo; rhabdomyolysis has been reported (rarely) with angiotensin-receptor antagonists.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F165908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to eprosartan or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F165894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with eprosartan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use eprosartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency and severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F165947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F165899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F165919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Dong quai has estrogenic activity. Some herbal medications may worsen hypertension (eg, ephedra); garlic may have additional antihypertensive effects. Management: Avoid dong quai if using for hypertension. Avoid ephedra, yohimbe, ginseng, and garlic.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F165900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F165911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     The use of drugs which act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Use is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F165932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F165910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Eprosartan Mesylate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (30): $102.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Teveten Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $393.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (100): $460.26",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13361415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Electrolytes, serum creatinine, BUN, urinalysis",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F165912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Futuran (ES);",
"     </li>",
"     <li>",
"      Teveten (AT, AU, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HK, HN, IE, KP, NL, NO, PH, PK, PL, PT, SE, TH, TW);",
"     </li>",
"     <li>",
"      Tevetens (ES);",
"     </li>",
"     <li>",
"      Tevetenz (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F165893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis. Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because eprosartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Eprosartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F165907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimally hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 300 mg dose: 13%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 5-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Fasting: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (90%); urine (7%, mostly as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: 7.9 L/hour",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN and Tognoni G, &ldquo;Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(23):1667-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/11759645/pubmed\" id=\"11759645\" target=\"_blank\">",
"        11759645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickstein K, Kjekshus J, et al, \"Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9335):752-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/12241832/pubmed\" id=\"12241832\" target=\"_blank\">",
"        12241832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein BJ and Gums JG, \"Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(3):470-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/15701766/pubmed\" id=\"15701766\" target=\"_blank\">",
"        15701766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granger CB, McMurray JJ, Yusuf S, et al, \"Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):772-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/13678870/pubmed\" id=\"13678870\" target=\"_blank\">",
"        13678870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al, \"Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):767-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/13678869/pubmed\" id=\"13678869\" target=\"_blank\">",
"        13678869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, \"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(2):203.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al, \"Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,\"",
"      <i>",
"       Lancet",
"      </i>",
"      ,  2000, 355(9215):1582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/10821361/pubmed\" id=\"10821361\" target=\"_blank\">",
"        10821361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/13/31958/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8917 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31958=[""].join("\n");
var outline_f31_13_31958=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708744\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165923\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165924\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165953\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165926\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165927\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165928\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165929\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165903\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165890\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165904\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165951\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165908\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165894\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165947\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165899\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165919\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165900\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165911\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165932\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165910\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13361415\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165912\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165893\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165907\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8917\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8917|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/34/6693?source=related_link\">",
"      Eprosartan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_13_31959="Endoscopic procedures in patients with disorders of hemostasis";
var content_f31_13_31959=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic procedures in patients with disorders of hemostasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/13/31959/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31959/contributors\">",
"     Patrick S Kamath, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/13/31959/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31959/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/13/31959/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31959/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/13/31959/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroenterologic procedures are commonly performed in patients with abnormal hemostasis. However, there are limited data assessing the bleeding risk of specific procedures in these settings.",
"   </p>",
"   <p>",
"    This topic will review the bleeding risks associated with endoscopic procedures, the risk of thromboembolic complications associated with various conditions, and the periprocedural management of patients with von Willebrand's disease, hemophilia, renal failure, liver failure, and thrombocytopenia. The management of patients taking anticoagulants or antiplatelet agents is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=see_link\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5702?source=see_link\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society for Gastrointestinal Endoscopy (ASGE) has issued official guidelines based upon the available evidence and consensus opinion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/1\">",
"     1",
"    </a>",
"    ]. The recommendations in this topic review are consistent with the ASGE guidelines. The guidelines can be found at",
"    <a class=\"external\" href=\"file://www.asge.org/PublicationsProductsindex.aspx?id=352\">",
"     www.asge.org/PublicationsProductsindex.aspx?id=352",
"    </a>",
"    . In addition, this topic review also addresses disorders of hemostasis not covered by the ASGE guidelines. This topic is also addressed in reviews from the American Journal of Gastroenterology and the Journal of the American College of Cardiology, which make similar recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROCEDURE-RELATED BLEEDING RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ASGE classifies the risk of bleeding from endoscopic procedures in patients with normal coagulation status as either high or low (",
"    <a class=\"graphic graphic_table graphicRef50700 \" href=\"mobipreview.htm?43/43/44731\">",
"     table 1",
"    </a>",
"    ) (see appropriate topic reviews).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-risk procedures (risk of bleeding 1 to 6 percent) include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Colonoscopic or gastric polypectomy",
"     </li>",
"     <li>",
"      Laser ablation and coagulation",
"     </li>",
"     <li>",
"      Endoscopic sphincterotomy",
"     </li>",
"     <li>",
"      Pneumatic or bougie dilation of benign or malignant strictures",
"     </li>",
"     <li>",
"      Percutaneous endoscopic gastrostomy tube placement",
"     </li>",
"     <li>",
"      Endoscopic ultrasound (EUS)-guided fine-needle aspiration",
"     </li>",
"     <li>",
"      Endoscopic hemostasis",
"     </li>",
"     <li>",
"      Therapeutic balloon assisted enteroscopy",
"     </li>",
"     <li>",
"      Tumor ablation by any technique",
"     </li>",
"     <li>",
"      Cystgastrostomy",
"     </li>",
"     <li>",
"      Treatment of varices",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-risk procedures (bleeding risk &lt;1 percent) include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Diagnostic upper endoscopy, flexible sigmoidoscopy, and colonoscopy (including biopsies)",
"     </li>",
"     <li>",
"      Diagnostic endoscopic retrograde cholangiopancreatography (ERCP)",
"     </li>",
"     <li>",
"      Biliary stent insertion without endoscopic sphincterotomy",
"     </li>",
"     <li>",
"      Endosonography",
"     </li>",
"     <li>",
"      Push enteroscopy and diagnostic balloon assisted enteroscopy",
"     </li>",
"     <li>",
"      Capsule endoscopy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, endoscopic techniques can be used to decrease the risk of bleeding. For example, in patients undergoing polypectomy, hemoclips may be placed at the polypectomy site. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11304?source=see_link&amp;anchor=H10#H10\">",
"     \"Bleeding after colonic polypectomy\", section on 'Prevention of immediate bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11304?source=see_link&amp;anchor=H16#H16\">",
"     \"Bleeding after colonic polypectomy\", section on 'Prevention of delayed bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK OF THROMBOEMBOLIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The probability of a thromboembolic complication following reversal or discontinuation of anticoagulation or antiplatelet agents depends upon the preexisting condition for which the medication was prescribed. The ASGE recognizes high- and low-risk conditions (",
"    <a class=\"graphic graphic_table graphicRef77634 \" href=\"mobipreview.htm?40/0/40971\">",
"     table 2",
"    </a>",
"    ). These issues are also discussed in detail on topic reviews focusing on the individual conditions (see appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     High-risk conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-risk conditions include atrial fibrillation associated with valvular heart disease (including the presence of a mechanical valve), mechanical valves in the mitral position, mechanical valves in patients who have had a prior thromboembolic event, coronary stents placed within one year, acute coronary syndrome, and nonstented percutaneous coronary intervention after myocardial infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mechanical heart valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of a thromboembolic complication arising from a mechanical heart valve depends upon the type of valve, its location, and coexisting structural or electrical disturbances in the heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The greatest risk is associated with mechanical valves located in the mitral or mitral and aortic positions. The risk is further increased with caged-ball or disk valves (compared with bileaflet or tilting dish valves) in patients with atrial fibrillation or a history of a prior embolic event. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25497?source=see_link&amp;anchor=H14#H14\">",
"     \"Complications of prosthetic heart valves\", section on 'Systemic embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal type and levels of anticoagulation should be individualized and based upon the location, type, and number of prosthetic valves, and the patient's age and comorbid conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjustment of anticoagulation for the performance of an endoscopic procedure in patients with atrial fibrillation is associated with an increase in stroke risk. Patients with atrial fibrillation that is associated with valvular heart disease, a dilated cardiomyopathy, or a history of a recent thromboembolic event are considered high-risk for thromboembolic complications.",
"   </p>",
"   <p>",
"    In a retrospective analysis of 1455 diagnostic gastrointestinal endoscopic procedures (including upper endoscopy and colonoscopy), anticoagulation was adjusted (withheld, reversed, or dose reduced) in 1027 patients and continued without adjustment in 428 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/6\">",
"     6",
"    </a>",
"    ]. At 30 days, 12 strokes (1.2 percent of patients) occurred in patients who had had their anticoagulation adjusted, whereas no strokes occurred in patients whose anticoagulation was continued. The stroke risk for atrial fibrillation in the absence of valvular heart disease was 0.3 percent. Factors increasing the stroke risk in patients whose anticoagulation was adjusted included age &gt;80 years, prior history of stroke, hypertension, hyperlipidemia, and family history of vascular disease. In patients undergoing endoscopies combined with other procedures or with comorbid illnesses, the stroke rate was as high as 2.9 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Coronary stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with coronary stents are at risk for stent thrombosis. This is especially a concern in patients with drug-eluting stents. Many patients are treated with dual antiplatelet therapy and the risk of thrombosis is increased if that therapy is discontinued early. The American Heart Association recommends that patients with drug-eluting stents receive dual antiplatelet therapy for a minimum of 12 months following stent placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Low-risk conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-risk conditions for thromboembolic complications include DVT, chronic or paroxysmal atrial fibrillation that is not associated with valvular disease, bioprosthetic valves, and mechanical valves in the aortic position. The overall risk for an embolic event in these patients is 1 to 2 per 1000 patients when anticoagulation is interrupted for four to seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Atrial fibrillation without other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of thromboembolism in patients with atrial fibrillation in the absence of valvular heart disease is approximately 5 percent per year in patients who are not anticoagulated, and these patients are not considered high-risk for thromboembolic complications if their anticoagulation is held for a short period of time. However, the risk of thromboembolic complications is increased in patients with valvular heart disease, dilated cardiomyopathies, or recent thromboembolic events. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Atrial fibrillation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Deep venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early cessation of anticoagulation for a short period of time does not appear to increase the risk of pulmonary embolism in patients with a deep venous thrombosis (DVT). However, it is preferable not to discontinue therapy, particularly if the procedure can be delayed until after a suitable period of anticoagulation has been achieved (typically three to six months). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of interrupting anticoagulation in patients with vascular grafts or with hypercoagulable states has not been well studied. The individual hypercoagulable states are discussed elsewhere (see corresponding topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PATIENTS TAKING ANTICOAGULANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients taking anticoagulants is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=see_link\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PATIENTS TAKING ANTIPLATELET AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients taking antiplatelet agents is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5702?source=see_link\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INHERITED DISORDERS OF HEMOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of inherited disorders of hemostasis may increase the risk of bleeding with gastrointestinal procedures and require specific preventive measures. We suggest consultation with an expert in coagulation disorders before performing endoscopic procedures in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     von Willebrand disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;von Willebrand disease is the most common inherited bleeding disorder, with an estimated prevalence in the general population of 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/8\">",
"     8",
"    </a>",
"    ]. Although it is primarily a congenital disorder, there are also acquired forms of the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/8/44169?source=see_link\">",
"     \"Classification and pathophysiology of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    von Willebrand factor (VWF) performs two critical functions in hemostasis: it acts as a bridging molecule for normal platelet adhesion and aggregation, and it acts as a carrier for factor VIII in the circulation, increasing the half-life of factor VIII five-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/9\">",
"     9",
"    </a>",
"    ]. von Willebrand disease occurs when VWF is deficient or qualitatively abnormal.",
"   </p>",
"   <p>",
"    Three types of the inherited form of von Willebrand disease have been recognized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/10\">",
"     10",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/8/44169?source=see_link\">",
"     \"Classification and pathophysiology of von Willebrand disease\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I - is the most common form and is due to reduced functional VWF",
"     </li>",
"     <li>",
"      Type II - is caused by a qualitative abnormality, resulting in defective interaction of VWF with platelets and the vessel wall",
"     </li>",
"     <li>",
"      Type III - is the most severe form, caused by markedly reduced levels of VWF in the plasma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment depends upon the type of von Willebrand disease and the procedure being performed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DDAVP - For diagnostic procedures and mucosal biopsies in patients with Type I disease, treatment with DDAVP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      ) is usually sufficient. DDAVP can cause vasospasm and should be used cautiously in patients with coronary artery disease. Patients should also be monitored for the development of hyponatremia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21866?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of von Willebrand disease\", section on 'Desmopressin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      von Willebrand factor - For therapeutic procedures in patients with Type I disease, and for all procedures in patients with Types II and III disease, replacement of VWF is required. Products available that contain VWF in high concentrations include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/12/198?source=see_link\">",
"       factor VIII concentrates",
"      </a>",
"      , purified VWF concentrates, and cryoprecipitate. Replacement therapy should be continued for two to three days in patients who had a mucosal biopsy. For patients who underwent a therapeutic procedure, replacement should continue for up to two weeks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21866?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of von Willebrand disease\", section on 'Replacement therapy with VWF'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hemophilia A and B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophilia A is an x-linked recessive disorder due to congenital factor VIII deficiency. Hemophilia B is less common, is also x-linked recessive, and is due to congenital factor IX deficiency. Patients with these disorders should be prepared for endoscopy as if they were having a life-threatening hemorrhage.",
"   </p>",
"   <p>",
"    In patients with factor VIII deficiency, the factor VIII activity should be raised by infusion of a factor VIII concentrate one hour before the procedure. Baseline and post infusion levels should be measured to determine that the response has been adequate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of hemophilia\", section on 'Replacement therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines are lacking with regard to factor replacement for endoscopic procedures. However, in patients undergoing major surgical procedures, an initial factor level of 60 to 100 percent is achieved for hemostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/11\">",
"     11",
"    </a>",
"    ]. A prophylactic level of 30 to 50 percent is then maintained until the wound has healed (typically 10 to 14 days). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of hemophilia\", section on 'Desired factor levels'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The principles are the same for patients with factor IX deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of hemophilia\", section on 'Replacement therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ACQUIRED DISORDERS OF HEMOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal failure, liver failure, and thrombocytopenia may all predispose to procedure-related bleeding. von Willebrand disease can also exist in an acquired form. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'von Willebrand disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased tendency to bleed is present in both acute and chronic renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This is most often manifested by skin hemorrhage and by bleeding at sites of surgery or trauma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uremic bleeding appears to correlate most closely with prolongation of the bleeding time, due primarily to impaired platelet function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Other coagulation parameters are generally intact in uremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/12\">",
"     12",
"    </a>",
"    ]. The platelet count is usually normal or only slightly reduced, and there is no prolongation of the prothrombin or partial thromboplastin times.",
"   </p>",
"   <p>",
"    The risk of bleeding with gastrointestinal endoscopic procedures cannot be accurately predicted from the bleeding time and there are relatively few data to guide optimal treatment to prevent bleeding. As a general rule, patients should be treated as though their risk of bleeding is increased, and preventive measures should be guided by the clinical situation. Options for improving platelet function include DDAVP, dialysis, estrogens, and correction of anemia, which are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with liver failure have a number of derangements in hemostasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33914?source=see_link\">",
"     \"Coagulation abnormalities in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Causes of coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolongation of the prothrombin time (PT) and partial thromboplastin time usually indicates impaired hepatic synthesis of coagulation factors or vitamin K deficiency.",
"   </p>",
"   <p>",
"    Other coagulation abnormalities are commonly present in patients with liver failure. Low fibrinogen levels may be due to the presence of structurally abnormal fibrinogen, increased fibrinolysis, and disseminated intravascular coagulation. Patients may also have thrombocytopenia and qualitative platelet dysfunction. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Thrombocytopenia'",
"    </a>",
"    below.) Administration of DDAVP may be beneficial in patients with qualitative platelet dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of coagulopathy is estimated using the number of seconds the PT is elevated above the control and the INR. However, the PT is not a sensitive measure of coagulation status in patients with cirrhosis. It is most sensitive to deficiency of factor VII and begins to prolong when factor VII levels are reduced to approximately 55 percent of normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/10\">",
"     10",
"    </a>",
"    ]. By contrast, the PT is least sensitive to factor II activity and does not prolong until factor II activity is reduced to approximately 15 percent of normal. As a general rule, procoagulant factor activity is normal when factor activities are in the range of 40 to 50 percent of normal.",
"   </p>",
"   <p>",
"    In an individual patient with liver failure, interpretation of changes in the INR may only be accurate when the same thromboplastin reagent is used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/17\">",
"     17",
"    </a>",
"    ]. Despite this limitation, the INR is used as an approximation of coagulation status in patients with liver failure. Confidence in the results increases if the laboratory is consistently using the same thromboplastin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33914?source=see_link&amp;anchor=H5858423#H5858423\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Prothrombin time (PT) and the International Normalized Ratio (INR)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are data to suggest that procedures may safely be carried out in patients with elevated INRs in the setting of cirrhosis. A study of 150 patients with cirrhosis undergoing variceal band ligation found that having an INR greater than 1.5 or a platelet count less than 50,000",
"    <span class=\"nowrap\">",
"     platelets/microL",
"    </span>",
"    were not predictors of postprocedure bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/18\">",
"     18",
"    </a>",
"    ]. However, until more data become available demonstrating that these patients are not at increased risk for procedure-related bleeding, we suggest correcting the INR to 1.4 to 1.7 before carrying out high-risk procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/10\">",
"     10",
"    </a>",
"    ]. In our experience, an INR less than 2.5 is generally adequate for mucosal biopsies.",
"   </p>",
"   <p>",
"    Correction of the INR is usually best accomplished by administration of vitamin K and infusion of fresh frozen plasma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15960?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of vitamin K\", section on 'Treatment of coagulopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical use of plasma components\", section on 'Fresh frozen plasma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In extreme settings, correction of the coagulopathy cannot be achieved adequately with FFP, particularly in patients who are severely volume overloaded. Case series have demonstrated that administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    (rFVIIa) is associated with improvement or normalization of the serum prothrombin time, improved control of bleeding, and prevention of bleeding due to invasive procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/19-25\">",
"     19-25",
"    </a>",
"    ]. However, in a controlled trial of cirrhotic patients with upper gastrointestinal bleeding, rFVIIa was not more effective than placebo, except possibly in a subgroup of patients with Child-Pugh B and C cirrhosis with variceal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=see_link&amp;anchor=H18#H18\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Coagulopathy of liver dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;No large prospective studies have established optimal strategies for giving prophylactic platelet transfusions in patients with thrombocytopenia. One set of recommendations suggests increasing the platelet count to greater than 50,000",
"    <span class=\"nowrap\">",
"     platelets/microL",
"    </span>",
"    before high-risk therapeutic procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31959/abstract/10\">",
"     10",
"    </a>",
"    ]. A platelet count of more than 20,000",
"    <span class=\"nowrap\">",
"     platelets/microL",
"    </span>",
"    may be adequate for low-risk procedures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19385?source=see_link&amp;anchor=H33#H33\">",
"     \"Evaluation and management of thrombocytopenia by primary care physicians\", section on 'Invasive procedures'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3\">",
"     'Procedure-related bleeding risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The situation is more complex in patients who have disorders associated with platelet destruction such as immune thrombocytopenia. In such patients, elective procedures should be postponed until therapy addressing the underlying condition has been instituted. In emergency settings, platelet infusions should be given to maintain a platelet count of at least 20,000 to",
"    <span class=\"nowrap\">",
"     30,000/microL.",
"    </span>",
"    Further infusions should be given if there is evidence of bleeding. Glucocorticoids and immunoglobulin may also be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of bleeding from endoscopic procedures can be classified as high or low. In general, diagnostic procedures are low-risk, whereas therapeutic procedures are high-risk (",
"      <a class=\"graphic graphic_table graphicRef50700 \" href=\"mobipreview.htm?43/43/44731\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Procedure-related bleeding risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The probability of a thromboembolic complication following reversal or discontinuation of anticoagulation or antiplatelet agents depends upon the preexisting condition for which the medication was prescribed (",
"      <a class=\"graphic graphic_table graphicRef77634 \" href=\"mobipreview.htm?40/0/40971\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk of thromboembolic complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disorders of hemostasis that may require treatment prior to gastrointestinal procedures include von Willebrand's disease, hemophilia A and B, renal failure, liver failure, and thrombocytopenia. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'von Willebrand disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Hemophilia A and B'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Renal failure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Liver failure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients taking anticoagulants is reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=see_link\">",
"       \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The management of patients taking antiplatelet agents is reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5702?source=see_link\">",
"       \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/1\">",
"      ASGE Standards of Practice Committee, Anderson MA, Ben-Menachem T, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/2\">",
"      Kwok A, Faigel DO. Management of anticoagulation before and after gastrointestinal endoscopy. Am J Gastroenterol 2009; 104:3085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/3\">",
"      Becker RC, Scheiman J, Dauerman HL, et al. Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. J Am Coll Cardiol 2009; 54:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/4\">",
"      Cannegieter SC, Rosendaal FR, Bri&euml;t E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/5\">",
"      Stein PD, Alpert JS, Copeland J, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1992; 102:445S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/6\">",
"      Blacker DJ, Wijdicks EF, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology 2003; 61:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/7\">",
"      King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/8\">",
"      Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/9\">",
"      Brinkhous KM, Sandberg H, Garris JB, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985; 82:8752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/10\">",
"      Van Os EC, Kamath PS, Gostout CJ, Heit JA. Gastroenterological procedures among patients with disorders of hemostasis: evaluation and management recommendations. Gastrointest Endosc 1999; 50:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/11\">",
"      Srivastava A. Dose and response in haemophilia--optimization of factor replacement therapy. Br J Haematol 2004; 127:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/12\">",
"      Eberst ME, Berkowitz LR. Hemostasis in renal disease: pathophysiology and management. Am J Med 1994; 96:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/13\">",
"      Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/14\">",
"      Steiner RW, Coggins C, Carvalho AC. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/15\">",
"      Escolar G, Cases A, Bastida E, et al. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 1990; 76:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/16\">",
"      Gawaz MP, Dobos G, Sp&auml;th M, et al. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994; 5:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/17\">",
"      Robert A, Chazouill&egrave;res O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology 1996; 24:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/18\">",
"      Vieira da Rocha EC, D'Amico EA, Caldwell SH, et al. A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation. Clin Gastroenterol Hepatol 2009; 7:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/19\">",
"      Chuansumrit A, Chantarojanasiri T, Isarangkura P, et al. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2000; 11 Suppl 1:S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/20\">",
"      Kaliciski P, Kamiski A, Drewniak T, et al. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplant Proc 1999; 31:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/21\">",
"      Kositchaiwat C, Chuansumrit A. Experiences with recombinant factor VIIa for the prevention of bleeding in patients with chronic liver disease undergoing percutaneous liver biopsies and endoscopic retrograde cholangiopancreatography (ERCP). Thromb Haemost 2001; 86:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/22\">",
"      Shami VM, Macik BG, Hespenheide EE, et al. Recombinant activated factor VII is superior to plasma alone in correcting the coagulopathy of fulminant hepatic failure (abstract). Hepatology 2001; 34:237A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/23\">",
"      Ejlersen E, Melsen T, Ingerslev J, et al. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 2001; 36:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/24\">",
"      Jeffers L, Chalasani N, Balart L, et al. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002; 123:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/25\">",
"      Caldwell SH, Chang C, Macik BG. Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials. Hepatology 2004; 39:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31959/abstract/26\">",
"      Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127:1123.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2553 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31959=[""].join("\n");
var outline_f31_13_31959=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROCEDURE-RELATED BLEEDING RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK OF THROMBOEMBOLIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      High-risk conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mechanical heart valves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Coronary stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Low-risk conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Atrial fibrillation without other risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Deep venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PATIENTS TAKING ANTICOAGULANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PATIENTS TAKING ANTIPLATELET AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INHERITED DISORDERS OF HEMOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hemophilia A and B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ACQUIRED DISORDERS OF HEMOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Liver failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Causes of coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2553\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2553|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/43/44731\" title=\"table 1\">",
"      Bleeding risk GI procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/0/40971\" title=\"table 2\">",
"      Risk GI procedure conditions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11304?source=related_link\">",
"      Bleeding after colonic polypectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19385?source=related_link\">",
"      Evaluation and management of thrombocytopenia by primary care physicians",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5702?source=related_link\">",
"      Management of antiplatelet agents in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=related_link\">",
"      Treatment of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_13_31960="Maylard incision";
var content_f31_13_31960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Maylard incision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 590px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse muscle-cutting incision. (A) Incision of rectus sheath is extended laterally to iliac spine to expose rectus muscle. Rectus muscles are cut transversly. (B) Cut edges of muscles are sutured to the rectus sheath. Ligated epigastric vessels and exposed transversalis fascia are shown. Transversalis fascia and peritoneum are incised transversely. Urachus is ligated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31960=[""].join("\n");
var outline_f31_13_31960=null;
var title_f31_13_31961="Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome";
var content_f31_13_31961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/13/31961/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31961/contributors\">",
"     Chadwick Miller, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31961/contributors\">",
"     Christopher B Granger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/13/31961/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31961/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31961/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31961/contributors\">",
"     Allan S Jaffe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/13/31961/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31961/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/13/31961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest pain accounts for approximately 6 million annual visits to emergency departments (ED) in the United States (US), making it the second most common ED complaint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients present with a spectrum of signs and symptoms reflecting the many potential etiologies of chest pain. Diseases of the heart, aorta, lungs, esophagus, stomach, mediastinum, pleura, and abdominal viscera may all cause chest discomfort.",
"   </p>",
"   <p>",
"    One of the most common causes of chest pain in patients who present for evaluation is acute coronary syndrome, accounting for approximately 12 to 15 percent of all cases of chest pain in the emergency department setting. The term acute coronary syndrome (ACS) is applied to patients in whom there is evidence of myocardial ischemia or infarction. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Criteria for diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic discusses the evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome (ACS) as assessed by the results of the initial history, physical exam, electrocardiogram (ECG) and initial biomarkers. The approach to other patients with chest pain or to those with a high likelihood of ACS is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20090?source=see_link\">",
"     \"Evaluation of chest pain in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach in this topic is generally consistent with that recommended in the 2010 American Heart Association scientific statement on testing of low-risk patients presenting to the emergency department with chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CRITERIA FOR DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term acute coronary syndrome (ACS) is applied to patients in whom there is evidence of myocardial ischemia or infarction. There are three types of acute coronary syndrome (ACS): ST elevation (formerly Q-wave) MI (STEMI); non-ST elevation (formerly non-Q wave) MI (NSTEMI); and unstable angina (UA). The first two are characterized by a typical rise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fall in biomarkers of myocyte injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/3\">",
"     3",
"    </a>",
"    ]. Unstable angina is characterized by myocardial ischemia without elevated biomarkers and is often a clinical diagnosis based on history, dynamic ECG changes or inducible ischemia on stress testing. Establishing whether a patient has acute coronary syndrome requires integration of information obtained from a careful patient interview and examination as well as from serial evaluation of the electrocardiogram (ECG), troponin levels, and occasionally provocative testing results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link&amp;anchor=H2#H2\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GOALS OF EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary focus in the evaluation of patients for ACS is to reasonably confirm or exclude in an expeditious manner ACS as a cause for the patient's symptoms. Reasonable confirmation of ACS is generally secured by the finding of an elevated troponin, diagnostic ECG changes, or abnormal provocative testing. ACS is reasonably excluded when the probability of ACS is below a 1 to 2 percent threshold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Related goals are to estimate risk of cardiac events in the ensuing days and weeks and to identify patients who will benefit from further cardiovascular evaluation and therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     STAGES OF EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are the sequential stages in the evaluation of patients at low or intermediate risk of ACS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prehospital",
"     </li>",
"     <li>",
"      Immediate in-hospital",
"     </li>",
"     <li>",
"      Prior to return of troponin level",
"     </li>",
"     <li>",
"      After return of a normal troponin level",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the goals of each stage differ somewhat, the following need to be accomplished in a timely manner:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid identification of patients with probable ST or non-ST elevation myocardial infarction (MI) so that rapid initiation of appropriate antithrombotic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reperfusion therapies can be initiated",
"     </li>",
"     <li>",
"      Elimination of other life-threatening illnesses from the differential diagnosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20090?source=see_link\">",
"       \"Evaluation of chest pain in the emergency department\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/16/28938?source=see_link\">",
"       \"Evaluation of the adult with dyspnea in the emergency department\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Assessment of the likelihood of ACS in patients at low or intermediate risk for ACS (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prior to return of troponin level'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Risk stratification to determine diagnostic strategies and to match treatment strategies with risk of adverse outcomes (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Risk stratification'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prehospital",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptoms of possible ACS (chest discomfort with or without radiation, shortness of breath, weakness, diaphoresis, nausea, or light-headedness) should generally be instructed to call 9-1-1 and be brought to the hospital by ambulance. Emergency Medical Service (EMS) evaluation and transport results in more rapid and focused evaluation by streamlining the triage process. While many patients, especially those without a cardiac history, contact health care providers with non-cardiac chest discomfort and will ultimately need only reassurance, it is important that a patient with possible myocardial ischemia be referred for urgent evaluation including an ECG, and biomarkers when appropriate.",
"   </p>",
"   <p>",
"    Prehospital evaluation and stabilization by care providers should include obtaining a 12-lead ECG, administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and administration of nitroglycerine if cardiac pain is suspected.",
"   </p>",
"   <p>",
"    A reperfusion protocol should be initiated prior to arrival at the most appropriate hospital in patients whose ECGs have evidence of acute ST elevation myocardial infarction (STEMI). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immediate in-hospital evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;On hospital arrival, patients with suspected ACS should have the following performed (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initiation of oxygen and continuous electrocardiographic monitoring and establishment of intravenous access.",
"     </li>",
"     <li>",
"      An initial 12 lead ECG should be obtained within 10 minutes of arrival, if one was not performed prehospital [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/3\">",
"       3",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      To identify ST-segment elevation MI, 12-lead ECGs should be obtained for patients age &ge;30 years with chest pain; age &ge;50 years with chest pain or other symptoms that could represent myocardial ischemia like shortness of breath, altered mental status, upper extremity pain, syncope, or generalized weakness (",
"      <a class=\"graphic graphic_table graphicRef74822 \" href=\"mobipreview.htm?5/5/5211\">",
"       table 1",
"      </a>",
"      ). Very elderly (&ge;80 years) with abdominal pain or",
"      <span class=\"nowrap\">",
"       nausea/vomiting",
"      </span>",
"      should have an immediate 12-lead ECG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/6\">",
"       6",
"      </a>",
"      ]. In patients clinically suspected of having an ACS in whom the ECG is nondiagnostic, it is recommended that the ECG be repeated at 20 to 30 minute intervals for any patient with ongoing pain in whom the suspicion of ACS remains high. Patients whose ECGs are diagnostic for or strongly suggestive of either STEMI or NSTEMI should be managed for those diagnoses. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"       \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A brief history and physical examination should be performed both to screen for signs or symptoms of cardiopulmonary distress and to establish a tentative rank list of possible causes of chest pain. The larger discussion of the initial diagnostic approach to patients with chest pain is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20090?source=see_link\">",
"       \"Evaluation of chest pain in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       Nitroglycerin",
"      </a>",
"      can be administered as a therapeutic intervention.",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in a dose of 162 to 325 mg unless there is a compelling contraindication or unless provided prehospital.",
"     </li>",
"     <li>",
"      Medications for symptom relief should be provided: Analgesics including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      for pain relief, antiemetics, and anxiolytics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If ACS remains as a possible cause of the patient's symptoms after completion of the above steps, a troponin level should be measured. This assumes that the patient's risk for ACS remains above some lower limit of likelihood, which is discussed in the next section.",
"   </p>",
"   <p>",
"    A chest roentgenogram is usually performed in patients suspected of having ACS, as alternative diagnoses such as aortic dissection, pulmonary embolism, or acute pericardial disease may be detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Threshold for evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;At some lower threshold of pretest probability, the clinician is more likely to cause harm by further testing. It has been suggested that an acceptable lower limit of pretest probability for ACS, above which further testing should be done, is two percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/4\">",
"     4",
"    </a>",
"    ]. Other researchers have attempted to define a lower limit of one percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, patients above a one to two percent pretest probability should receive further testing, whereas those below one to two percent are very low risk and unlikely to benefit from additional testing.",
"   </p>",
"   <p>",
"    Presently two tools exist that may be helpful to identify these very low risk patients: an experienced clinician's unstructured clinical estimate of &lt;2 percent risk and a computer algorithm derived estimate (attribute matching) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/7\">",
"     7",
"    </a>",
"    ]. Both were able to classify approximately 25 percent of chest pain patients as &lt;2 percent risk. Event rates among those classified as &lt;2 percent risk were low (0.3 percent, 95% CI 0%-1.8% attribute matching; 0.7 percent, 95% CI 0%-2.4% unstructured clinical estimate). These data suggest that either of these methods can be used to define patients at very low risk for ACS.",
"   </p>",
"   <p>",
"    When formulating the clinician's pretest probability, it is important to avoid over-reliance on an alternative diagnosis. In patients being evaluated for chest pain, it has been shown that those with a \"clear-cut\" alternative noncardiac diagnosis still have a 4 percent rate of ACS at 30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/8\">",
"     8",
"    </a>",
"    ]. Similarly, patients with a \"clear-cut\" alternative noncardiac diagnosis and a TIMI risk score of 0 had a 2.9 percent rate of ACS at 30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/9\">",
"     9",
"    </a>",
"    ]. Among patients with ACS, a common misdiagnosis is gastroesophageal reflux disease. In two different datasets it has been shown that patients with ACS commonly describe their pain as burning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Certain populations also have increased risk for missed ACS. Four populations that are more likely to be discharged from the emergency department with ACS include: Women &lt;55 years old, nonwhite patients, dyspnea as the primary complaint, and patients with a normal ECG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/10\">",
"     10",
"    </a>",
"    ]. We recommend that clinicians incorporate all data elements when forming an unstructured estimate of ACS probability, avoid over-reliance on the presence of an alternative diagnosis, and use caution when defining the very low-risk patient population.",
"   </p>",
"   <p>",
"    In summary, we suggest that when clinician's estimate of the patient's likelihood of ACS is very low (&lt;2 percent) no further testing for ACS be performed. Patients who are diagnosed with chest pain and chronic stable angina may benefit from outpatient stress testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiac biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those patients who have more than a \"very low\" (&lt;2 percent) likelihood of ACS, as described in the preceding section, the first of two or three biomarker assessments should be performed. Most experts now believe that the results of the first set of biomarkers should be available within 60 minutes. Troponin is preferred over creatine kinase-MB because of its increased specificity and sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/3\">",
"     3",
"    </a>",
"    ]. In most patients, two sets of troponin are required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link&amp;anchor=H7#H7\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\", section on 'Diagnosis of primary MI'",
"    </a>",
"    .) In select patients, a single marker may be sufficient if the onset of chest pain was six to eight hours prior to presentation and the pain was an isolated episode that has not recurred, or has been continuous since onset. No biomarker approach can exclude unstable angina.",
"   </p>",
"   <p>",
"    The finding of a positive biomarker should prompt caregivers to consider management protocol for NSTEMI. However, a rise or fall of troponin is more specific for the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The second set of biomarkers should generally be performed four to six hours after the first. If earlier diagnosis is desirable, a second biomarker measurement at two to three hours may be used.",
"   </p>",
"   <p>",
"    The final biomarker determination should be obtained 8 to 12 hours, or even 24 hours after the onset of symptoms in patients in whom the clinical suspicion of ACS is high, in accordance with the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consistent with the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, at the conclusion of serial biomarkers, most patients will have been observed for approximately eight hours. Due to the delay between symptom onset and presentation, most patients are observed 12 hours from symptom onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Abbreviated cardiac biomarker strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple approaches have been evaluated to obtain the cardiac biomarker information in a shorter time period (less than six hours) and thus potentially identify patients who can be discharged early. While these approaches show promise, they require that institutions establish their own cutoff for a \"positive\" change. As a result, they have not yet gained widespread adoption.",
"    <br/>",
"    <br/>",
"    This approach was initially tested using CK-MB and showed promise (relatively good sensitivity for the diagnosis of MI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. However, as troponin is the preferred biomarker for the diagnosis of MI, these early studies are not directly relevant to current practice.",
"    <br/>",
"    <br/>",
"    Approaches using multiple point-of care biomarkers and clinical variables have been assessed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/3,13-15\">",
"     3,13-15",
"    </a>",
"    ]. While these studies have showed some promise with regard to the facilitation of early discharge in very low risk patients, the use of point-of-care assays and multiple biomarkers might be unnecessary with the use of higher sensitivity troponin tests that are currently available. The role of very high-sensitivity troponins tests, not yet approved for use in the United States, shows promise in redefining how rapid serial measures may be used to identify very low risk patients",
"   </p>",
"   <p>",
"    <br/>",
"    At least three prospective validation studies have attempted to identify chest pain patients at very low risk of ACS using a combination of clinical parameters and current generation high sensitivity troponin values. The HEART score, [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] the North American Chest Pain Rule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/18\">",
"     18",
"    </a>",
"    ], and the accelerated diagnostic protocol developed from the ADAPT study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/19\">",
"     19",
"    </a>",
"    ] show promise, but each needs further multicenter prospective confirmation of their value in diagnosing ACS and related risk before widespread application. Most notably, these decision aids have been prospectively validated in observational studies, but have not been implemented to discharge patients home.",
"   </p>",
"   <p>",
"    The ADAPT trial is an important addition to the growing literature on abbreviated cardiac biomarker strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/19\">",
"     19",
"    </a>",
"    ]. ADAPT was a prospective, observational study of nearly 2000 patients with chest pain due to suspected ACS that evaluated an accelerated diagnostic protocol. The protocol included pre-test probability scoring by the Thrombolysis In Myocardial Infarction (TIMI) risk score, electrocardiography, and 0 and 2 hour troponin I values. In ADAPT, the accelerated diagnostic protocol successfully identified very low risk patients; the sensitivity and a negative predictive value were 99.7 percent for the primary endpoint of major adverse cardiac events within 30 days. However, as the authors acknowledge, some of these effects could have been due in part to the close aggressive follow-up care provided during which many patients had stress procedures and additional diagnostic and therapeutic interventions as necessary. Limitations of this study include the uncertainty of generalizability to other troponin assays and the possibility of misclassification due to co-intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/20\">",
"     20",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    For now, use of change in two-hour biomarker measurements in combination with clinical and ECG findings, when used, will need to be customized to the specific institution in part based on the specific troponin assay being used. Patients without significant changes could then be considered for earlier cardiac imaging. Cardiac imaging that allows assessment of resting myocardial perfusion prior to stress testing (if the resting test is normal) should be favored given that such a protocol can be expected to miss some patients with acute myocardial infarction. An alternative would be to use an abbreviated cardiac biomarker strategy integrated with one of the decision aids listed above to determine patients at very low risk for ACS who do not need cardiac imaging. The decision to pursue this option should be coordinated with the patient and follow-up should be available. Ideally, this option would be adopted at the institution-level and combined with outcome surveillance. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Further diagnostic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PRIOR TO RETURN OF TROPONIN LEVEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in whom the diagnosis of ACS is still likely after the initial history, examination and serial ECGs have been performed, and who are awaiting the results of the serum troponin, should have an assessment of the likelihood of ACS. While risk assessment tools such as the Thrombolysis in Myocardial Infarction (TIMI) and Global Registry of Acute Cardiac Events (GRACE) scores have been developed, they include the troponin level and thus are not useful at this early stage of patient care. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Risk stratification'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We use an approach similar to that recommended by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    in their 2007",
"    <span class=\"nowrap\">",
"     UA/NSTEMI",
"    </span>",
"    guideline update which uses elements of the history, physical examination, and ECG to determine high, intermediate or low likelihood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/3\">",
"     3",
"    </a>",
"    ]. High likelihood characteristics include chest pain similar to prior anginal pain, hypotension, diaphoresis, findings of heart failure, or new or dynamic ECG changes (",
"    <a class=\"graphic graphic_table graphicRef51033 \" href=\"mobipreview.htm?34/58/35756\">",
"     table 2",
"    </a>",
"    ). Patients assessed to be at high risk but with a nondiagnostic ECG should be given a tentative diagnosis of ACS and managed as such. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain patient populations are more likely to present with \"atypical\" presentations such as shortness of breath, nausea and vomiting, or weakness, without chest pain. It is important to recognize ACS when evaluating these patients, including the elderly, women, and patients with diabetes.",
"   </p>",
"   <p>",
"    Patients who are felt to be at low or intermediate risk should be monitored with continuous ECG rhythm monitoring. Any changes in clinical condition should prompt reassessment. Serial ECGs should be performed on patients with continuous pain to detect dynamic changes. Administration of the previously mentioned therapies should be completed.",
"   </p>",
"   <p>",
"    Care providers should also simultaneously be evaluating other elements of the differential diagnosis of the patient's symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20090?source=see_link\">",
"     \"Evaluation of chest pain in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/16/28938?source=see_link\">",
"     \"Evaluation of the adult with dyspnea in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     AFTER RETURN OF TROPONIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next stage of the patient's care begins after the return of the troponin. Once the patient's likelihood of an adverse event has been calculated (risk stratification), using tools that take the value of the troponin into account, the next step in management can be determined.",
"   </p>",
"   <p>",
"    The presence of either an elevated troponin or ongoing chest pain or new ECG changes with a normal troponin, mandates that the patient be managed for an ACS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even in patients with normal or nondiagnostic ECG, normal biomarkers, and low risk for adverse events, up to 10 percent may still have ACS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/4\">",
"     4",
"    </a>",
"    ] and 2 to 4 percent may have early adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/5,21\">",
"     5,21",
"    </a>",
"    ] Thus, subsequent noninvasive provocative testing is an important part of the evaluation of these low-risk patients with possible acute coronary syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have not been triaged into an ACS care plan should have their risk of adverse short-term outcomes (30 day risk of death, nonfatal MI, or recurrent ischemia) assessed using tools such as the TIMI and GRACE risk scores. The purpose of this next level of risk assessment is to allow for the determination of subsequent testing and disposition, and to guide interim medical therapies. The TIMI and GRACE risk scores are also discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2746?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'Early risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     TIMI risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI risk prediction score has proven predictive ability in patients with suspected or known ACS and has undergone multiple validation investigations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/22\">",
"     22",
"    </a>",
"    ]. The TIMI score (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) was derived and validated in patients with ACS, but has since been validated in patients suspected to have ACS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/23\">",
"     23",
"    </a>",
"    ]. Because of its simplicity, and lack of a need for a nomogram or computer algorithm, and because it predicts risk of short-term (30 days) outcome, it has been fairly popular and widely adopted in the ED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the elements of the TIMI risk score, troponin elevation was the most powerful factor. However, even TIMI 0 patients had a significant 2.1 percent incidence of the composite outcome. The TIMI risk score is part of the process described above. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'After return of troponin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An evaluation of the ability of the TIMI risk score of 0, in addition to a normal troponin and ECG, to predict adverse outcomes found one major adverse cardiovascular event (a revascularization) within seven days among 215 patients who met the criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/24\">",
"     24",
"    </a>",
"    ]. It should be noted that these patients had close follow-up and extensive testing on an outpatient basis after discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     GRACE risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GRACE risk score stratifies the risk of death among patients with ACS both during the index hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/25\">",
"     25",
"    </a>",
"    ] and at one year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/26\">",
"     26",
"    </a>",
"    ]. This model was developed in a registry population of unselected hospitalized patients with suspected ACS, and has been validated in multiple populations. However, cutoffs to determine low, intermediate, and high risk using the GRACE risk score have not been firmly established in patients with undifferentiated chest pain.",
"   </p>",
"   <p>",
"    The HEART score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/16\">",
"     16",
"    </a>",
"    ] has been recently validated at four sites in The Netherlands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/17\">",
"     17",
"    </a>",
"    ]. The HEART score uses similar components to the TIMI risk score, but also incorporates clinical impression. The validation of this score suggested that it may be able to predict a very low-risk population. However, further validation is necessary in a larger population and including EDs in the US before we can advocate implementation for this purpose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although precision is not possible when estimating the likelihood of short-term cardiac events, the assessment should be used to guide diagnostic and treatment decisions. We recommend stratifying ED patients with the TIMI risk score (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) as it has been validated in patients suspected of ACS in the ED. However, it is important to incorporate the caregiver&rsquo;s clinical impression into decision making. Further, it is also reasonable to use an abbreviated cardiac biomarker strategy with a validated decision aid such as the ADP (described above) to identify patients for discharge without provocative testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Management based on risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients will have been assessed to be at high risk, despite a normal biomarker, because of the presence of ongoing chest pain or new ECG changes. These patients should be admitted and managed as unstable angina. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients in whom the clinician is still concerned about a potential ACS, despite a normal first biomarker, further cardiac testing is indicated. Such patients may be cared for in the emergency department, in an observation unit, or are admitted.",
"   </p>",
"   <p>",
"    These low- or intermediate-risk patients (as defined by the risk scores discussed above) with possible but not definite ACS in whom the ECG and initial cardiac biomarkers are either normal or indeterminate should be monitored for 6 to 24 hours in a chest pain observation unit, step down unit, floor bed, or the emergency department [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/27-32\">",
"     27-32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Risk stratification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Observation unit approach",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Proof of safety and efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observation units can take several forms. At the most basic level, observation is a patient status during which ongoing testing occurs in the ED. The more common scenario is a specialized area, under control of either ED physicians, inpatient physicians, or both, in which patients receive ongoing testing and monitoring in a systematic way.",
"   </p>",
"   <p>",
"    Chest pain evaluation protocols have been designed to shorten the time required for chest pain diagnostic evaluation. Strategies to expedite the evaluation have incorporated at least one of the following: Abbreviated cardiac biomarker strategies, immediate or early cardiac imaging or stress testing. Each of these strategies is discussed below.",
"   </p>",
"   <p>",
"    Chest Pain Observation units (CPUs) or Clinical Decision Units (CDUs) are a safe and efficient use of resources to evaluate patients with chest pain with both intermediate and low probability of having ACS. Their use among patients with possible ACS receives a class I recommendation in the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/3\">",
"     3",
"    </a>",
"    ]. In a study of over 1000 mostly low risk patients, the discharge rate was 82 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/33\">",
"     33",
"    </a>",
"    ]. Since that time, randomized trials have proven their effectiveness and safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/28,32\">",
"     28,32",
"    </a>",
"    ], including one single center trial of 424 patients at intermediate risk for having ACS demonstrating observation units decreased resource utilization without increasing risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/28\">",
"     28",
"    </a>",
"    ]. However, a recent cluster randomized trial of observation unit implementation has questioned the improvement in resource utilization at 14 EDs in the UK, in which there was no decrease in admission rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/34\">",
"     34",
"    </a>",
"    ]. A comparison of inpatient short-stay units to ED observation units was recently completed among 332 ED patients with chest pain at one center demonstrating that both are safe and cost effective options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of assigning patients to CPUs has been demonstrated in multiple studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In one study, 424 patients at intermediate risk for ACS were randomly assigned to further evaluation in an emergency department CPU or hospital admission with cardiac monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/28\">",
"     28",
"    </a>",
"    ]. Although there was no significant difference in the rate of cardiac events, the CPU group incurred significantly less cost. No cardiac events occurred among patients evaluated and discharged from the CPU. The use of hospitalists to manage CPU patients may further reduce costs and length of stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies suggest that patients with chest pain at low risk for ACS do not require continuous cardiac monitoring. In one study, 1029 low-risk patients with chest pain were admitted to monitored beds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/37\">",
"     37",
"    </a>",
"    ]. Cardiac monitoring detected no episodes of sustained ventricular tachycardia or ventricular fibrillation, and there were no preventable deaths. However, until further evidence supports this point of view, we believe that all patients should be monitored in a CPU.",
"   </p>",
"   <p>",
"    A clinical trial demonstrated a reduction in hospital cost associated with observation unit care combined with stress cardiac MRI testing compared to inpatient care in non-low-risk patients, including those with prior coronary events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Which patients are suitable",
"    </span>",
"    &nbsp;&mdash;&nbsp;A controversial area in observation unit care is the inclusion of patients with known coronary disease, or those who are unable to exercise. Many studies of chest pain observation units excluded patients with known coronary disease. Similarly, most excluded patients unable to exercise. In principle, however, an observation unit is appropriate for any patient in whom serial negative ECGs, biomarkers, and cardiac imaging will identify a situation where hospital admission will not be necessary. Additionally, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines support managing these patients in observation units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/3\">",
"     3",
"    </a>",
"    ]. Therefore, we recommend this as an option in centers equipped to conduct this evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FURTHER DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the above evaluation to the point of the return of the first biomarker, should take one to three hours. If the patient has a negative initial troponin and no signs of ischemia on the first ECG,",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    can undergo serial ECG and serial markers to exclude cardiac necrosis.",
"   </p>",
"   <p>",
"    If serial ECGs and markers are negative, and the patient is stable,",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    should generally undergo noninvasive testing to further evaluate ACS as the cause of chest pain, unless the patient has been given an alternate diagnosis or an ACS is no longer assessed to be likely. Patients who might fall into this latter group include those with less than a 1 to 2 percent pretest probability of ACS as a cause of the patient's symptoms, as they are at very low risk. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Threshold for evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We acknowledge that recommendations regarding the management of these patients may change if and when the role of high sensitivity troponin assays in this setting has been clarified.",
"   </p>",
"   <p>",
"    For those patients in whom a decision is made to perform further testing, the timing and location should be guided by patient and institutional characteristics. Patients for whom there is a concern about the reliability of follow-up should undergo testing prior to discharge. For all patients undergoing further testing, we believe it is reasonable to obtain such testing within 72 hours; others have suggested that a longer interval is reasonable.",
"   </p>",
"   <p>",
"    Irrespective of whether further testing is performed, we recommend that all discharged patients be instructed in the importance of following discharge instructions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Choice of test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a summary of our approach to noninvasive testing of patients with chest pain at low or intermediate risk for ACS for whom further testing has been recommended. The preferred method of stress is exercise, for all patients who are able to do so. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/56/29578?source=see_link\">",
"     \"Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stress testing is recommended for low-risk patients without recurrent ischemic discomfort and if cardiac biomarker measurements after at least six to eight hours of observation (or 12 hours from symptom onset) are normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with the above characteristics and an ECG that is interpretable for ischemic changes can undergo exercise ECG test.",
"     </li>",
"     <li>",
"      Patients who are unable to exercise should undergo pharmacologic stress testing combined with imaging (vasodilator stress rMPI or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiography).",
"     </li>",
"     <li>",
"      Patients who have an uninterpretable ECG for ischemia (eg, LBBB, ventricular paced rhythm, LVH with strain pattern, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      therapy) should undergo stress testing with imaging (either rMPI or echocardiography).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninvasive rest imaging may be performed on patients with low-to-intermediate probability of ACS and no prior history of myocardial infarction who have ongoing or recent chest pain (or equivalent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with ongoing chest pain, we recommend either injection with radioactive isotope for rMPI or rest 2D-echocardiography.",
"     </li>",
"     <li>",
"      For patients who present within two hours of symptoms and diagnostic imaging is performed, we suggest rest radionuclide myocardial perfusion imaging (rMPI). However, a negative study does not exclude unstable angina. In many cases it should be followed by some form of stress testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Outpatient stress testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with possible ACS, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines support outpatient stress testing if it can be arranged within 72 hours of discharge. Candidates for outpatient stress testing should be low risk (",
"    <a class=\"graphic graphic_table graphicRef65662 \" href=\"mobipreview.htm?19/21/19805\">",
"     table 3",
"    </a>",
"    ) for death or MI based on",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    criteria have been observed for 6 to 12 hours and have no evidence of infarction on serial cardiac biomarker determinations, no recurrent symptoms of ischemia, and normal ECGs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/39\">",
"     39",
"    </a>",
"    ]. However, given concerns about unpredictable patient follow-up and the low but important residual risk of discharging a patient with an ACS, we generally prefer that noninvasive testing be completed before discharge if feasible, unless a reliable follow-up system is in place. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/56/29578?source=see_link&amp;anchor=H17#H17\">",
"     \"Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome\", section on 'Inpatient or outpatient'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CONSULTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for cardiology consultation will vary among institutions. The following are reasonable indications for obtaining consultation from a cardiologist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definite evidence for ACS, or when chest pain is accompanied by acute heart failure or hemodynamic instability.",
"     </li>",
"     <li>",
"      ECG with difficult-to-interpret ST segments (including paced rhythm or old LBBB) should have low threshold for consultation.",
"     </li>",
"     <li>",
"      Biomarker elevation that may or may not represent ACS.",
"     </li>",
"     <li>",
"      High likelihood that signs and symptoms represent ACS (",
"      <a class=\"graphic graphic_table graphicRef51033 \" href=\"mobipreview.htm?34/58/35756\">",
"       table 2",
"      </a>",
"      ), high short-term risk of death or nonfatal MI (",
"      <a class=\"graphic graphic_table graphicRef65662 \" href=\"mobipreview.htm?19/21/19805\">",
"       table 3",
"      </a>",
"      ), and patients with refractory chest pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31961/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with a known history of coronary artery disease with stress tests that are more difficult to interpret.",
"     </li>",
"     <li>",
"      Imaging reveals ongoing or inducible ischemia, significant coronary artery stenosis, or indeterminate results. Consultation may also be considered for patients with a known history of coronary artery disease as their tests are more difficult to interpret.",
"     </li>",
"     <li>",
"      Complicated cardiac histories, such as multiple prior coronary revascularization procedures.",
"     </li>",
"     <li>",
"      Need for assistance with disposition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     FINAL DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final disposition decision in most patients will occur after clinical observation, serial cardiac markers, serial ECGs, and cardiac stress testing or imaging:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with indeterminate stress testing or imaging results may benefit from cardiology consultation if not already obtained. Many such patients will be admitted.",
"     </li>",
"     <li>",
"      Patients with positive stress testing or imaging results should be evaluated by a cardiologist and admitted to the hospital.",
"     </li>",
"     <li>",
"      If the results of this testing are negative for a cardiac cause, and other life threatening components of the differential diagnosis have been ruled out, discharge home is appropriate for stable patients. These patients are labeled as having noncardiac chest pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a small percentage of patients with ACS are given a diagnosis of noncardiac chest pain, we suggest the following at the time of discharge:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide care for the most likely cause of pain.",
"     </li>",
"     <li>",
"      Inform the patient about the basis for the presumptive diagnosis and discuss areas of uncertainty in the diagnosis.",
"     </li>",
"     <li>",
"      Establish a plan for follow-up with a care provider, ideally within 72 hours.",
"     </li>",
"     <li>",
"      Provide clear and concise written discharge instructions that describe specific reasons for reevaluation and where and when to return.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary focus of the evaluation of patients with possible acute coronary syndrome (ACS) is to confirm or exclude the diagnosis in a reasonable but expeditious manner. Reasonable confirmation of ACS is generally secured by the finding of a classic presentation in a high-risk patient, an elevated troponin, diagnostic ECG changes, or abnormal provocative testing. Those patients who are identified as having an ACS or who are at high risk should be managed according to accepted standards. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exclusion of ACS often requires significant time and effort from caregivers: Serial electrocardiograms, a history and physical examination, serial biomarkers, and often noninvasive cardiac testing are part of this process. ACS is reasonably excluded when the probability of ACS is below a one to two percent threshold, and the evaluation for ACS may stop at that point. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Stages of evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Evaluation of patients who have neither been confirmed nor excluded from a diagnosis of ACS included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Make an initial determination of the likelihood of ACS after the history, physical examination and serial (two or three) electrocardiograms have been performed (",
"      <a class=\"graphic graphic_table graphicRef51033 \" href=\"mobipreview.htm?34/58/35756\">",
"       table 2",
"      </a>",
"      ). Consider alternative life-threatening diagnoses. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prior to return of troponin level'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reassess the likelihood of ACS and assess the short-term risk of an adverse event after return of the first and second biomarkers. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'After return of troponin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If after reassessment, the patient is felt to be at low or intermediate risk of an adverse event, noninvasive diagnostic testing is generally performed. Testing varies according to patient characteristics and is described briefly above and in greater detail separately. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Further diagnostic testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/56/29578?source=see_link\">",
"       \"Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After completion of the appropriate noninvasive diagnostic test (eg, stress test) determine the patient's final disposition. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Final disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     McCaig, L, Burt, C. National Hospital Ambulatory Medical Care Survey: 2003 Emergency Department Summary. In: Advance Data from Vital and Health Statistics. Centers for disease control and prevention, Atlanta, GA 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/2\">",
"      Amsterdam EA, Kirk JD, Bluemke DA, et al. Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. Circulation 2010; 122:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/3\">",
"      Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/4\">",
"      Kline JA, Johnson CL, Pollack CV Jr, et al. Pretest probability assessment derived from attribute matching. BMC Med Inform Decis Mak 2005; 5:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/5\">",
"      Marsan RJ Jr, Shaver KJ, Sease KL, et al. Evaluation of a clinical decision rule for young adult patients with chest pain. Acad Emerg Med 2005; 12:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/6\">",
"      Glickman SW, Shofer FS, Wu MC, et al. Development and validation of a prioritization rule for obtaining an immediate 12-lead electrocardiogram in the emergency department to identify ST-elevation myocardial infarction. Am Heart J 2012; 163:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/7\">",
"      Mitchell AM, Garvey JL, Chandra A, et al. Prospective multicenter study of quantitative pretest probability assessment to exclude acute coronary syndrome for patients evaluated in emergency department chest pain units. Ann Emerg Med 2006; 47:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/8\">",
"      Hollander JE, Robey JL, Chase MR, et al. Relationship between a clear-cut alternative noncardiac diagnosis and 30-day outcome in emergency department patients with chest pain. Acad Emerg Med 2007; 14:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/9\">",
"      Campbell CF, Chang AM, Sease KL, et al. Combining Thrombolysis in Myocardial Infarction risk score and clear-cut alternative diagnosis for chest pain risk stratification. Am J Emerg Med 2009; 27:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/10\">",
"      Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/11\">",
"      Fesmire FM, Hughes AD, Fody EP, et al. The Erlanger chest pain evaluation protocol: a one-year experience with serial 12-lead ECG monitoring, two-hour delta serum marker measurements, and selective nuclear stress testing to identify and exclude acute coronary syndromes. Ann Emerg Med 2002; 40:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/12\">",
"      Fesmire FM, Christenson RH, Fody EP, Feintuch TA. Delta creatine kinase-MB outperforms myoglobin at two hours during the emergency department identification and exclusion of troponin positive non-ST-segment elevation acute coronary syndromes. Ann Emerg Med 2004; 44:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/13\">",
"      Goodacre SW, Bradburn M, Cross E, et al. The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart 2011; 97:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/14\">",
"      Than M, Cullen L, Reid CM, et al. A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet 2011; 377:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/15\">",
"      Mitchell AM, Garvey JL, Kline JA. Multimarker panel to rule out acute coronary syndromes in low-risk patients. Acad Emerg Med 2006; 13:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/16\">",
"      Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value of the HEART score. Neth Heart J 2008; 16:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/17\">",
"      Backus BE, Six AJ, Kelder JC, et al. Chest pain in the emergency room: a multicenter validation of the HEART Score. Crit Pathw Cardiol 2010; 9:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/18\">",
"      Hess EP, Brison RJ, Perry JJ, et al. Development of a clinical prediction rule for 30-day cardiac events in emergency department patients with chest pain and possible acute coronary syndrome. Ann Emerg Med 2012; 59:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/19\">",
"      Than M, Cullen L, Aldous S, et al. 2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. J Am Coll Cardiol 2012; 59:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/20\">",
"      Hess EP, Jaffe AS. Evaluation of patients with possible cardiac chest pain: a way out of the jungle. J Am Coll Cardiol 2012; 59:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/21\">",
"      Braunwald E, Jones RH, Mark DB, et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994; 90:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/22\">",
"      Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/23\">",
"      Pollack CV Jr, Sites FD, Shofer FS, et al. Application of the TIMI risk score for unstable angina and non-ST elevation acute coronary syndrome to an unselected emergency department chest pain population. Acad Emerg Med 2006; 13:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/24\">",
"      Kelly AM. What is the incidence of major adverse cardiac events in emergency department chest pain patients with a normal ECG, thrombolysis in myocardial infarction score of zero and initial troponin &lt;=99th centile: an observational study? Emerg Med J 2013; 30:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/25\">",
"      Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/26\">",
"      Yan AT, Yan RT, Tan M, et al. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J 2007; 28:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/27\">",
"      Martinez E, Reilly BM, Evans AT, Roberts RR. The observation unit: a new interface between inpatient and outpatient care. Am J Med 2001; 110:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/28\">",
"      Farkouh ME, Smars PA, Reeder GS, et al. A clinical trial of a chest-pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators. N Engl J Med 1998; 339:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/29\">",
"      Graff LG, Dallara J, Ross MA, et al. Impact on the care of the emergency department chest pain patient from the chest pain evaluation registry (CHEPER) study. Am J Cardiol 1997; 80:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/30\">",
"      Roberts RR, Zalenski RJ, Mensah EK, et al. Costs of an emergency department-based accelerated diagnostic protocol vs hospitalization in patients with chest pain: a randomized controlled trial. JAMA 1997; 278:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/31\">",
"      deFilippi CR, Tocchi M, Parmar RJ, et al. Cardiac troponin T in chest pain unit patients without ischemic electrocardiographic changes: angiographic correlates and long-term clinical outcomes. J Am Coll Cardiol 2000; 35:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/32\">",
"      Goodacre S, Nicholl J, Dixon S, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ 2004; 328:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/33\">",
"      Gibler WB, Runyon JP, Levy RC, et al. A rapid diagnostic and treatment center for patients with chest pain in the emergency department. Ann Emerg Med 1995; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/34\">",
"      Goodacre S, Cross E, Lewis C, et al. Effectiveness and safety of chest pain assessment to prevent emergency admissions: ESCAPE cluster randomised trial. BMJ 2007; 335:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/35\">",
"      Jibrin I, Hamirani YS, Mitikiri N, et al. Maryland's first inpatient chest pain short stay unit as an alternative to emergency room-based observation unit. Crit Pathw Cardiol 2008; 7:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/36\">",
"      Krantz MJ, Zwang O, Rowan SB, et al. A cooperative care model: cardiologists and hospitalists reduce length of stay in a chest pain observation unit. Crit Pathw Cardiol 2005; 4:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/37\">",
"      Hollander JE, Sites FD, Pollack CV Jr, Shofer FS. Lack of utility of telemetry monitoring for identification of cardiac death and life-threatening ventricular dysrhythmias in low-risk patients with chest pain. Ann Emerg Med 2004; 43:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31961/abstract/38\">",
"      Miller CD, Hwang W, Hoekstra JW, et al. Stress cardiac magnetic resonance imaging with observation unit care reduces cost for patients with emergent chest pain: a randomized trial. Ann Emerg Med 2010; 56:209.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson, JL, Adams, CD, Antman, EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1. Available at: www.acc.org/qualityandscience/clinical/statements.htm (accessed July 28,2008).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-422ACB6E1F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31961=[""].join("\n");
var outline_f31_13_31961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CRITERIA FOR DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GOALS OF EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      STAGES OF EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prehospital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immediate in-hospital evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Threshold for evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiac biomarkers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Abbreviated cardiac biomarker strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PRIOR TO RETURN OF TROPONIN LEVEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      AFTER RETURN OF TROPONIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - TIMI risk score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - GRACE risk score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Management based on risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Observation unit approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Proof of safety and efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Which patients are suitable",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FURTHER DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Choice of test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Outpatient stress testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CONSULTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      FINAL DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/88\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/88|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/5/5211\" title=\"table 1\">",
"      Criteria 12 lead ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/58/35756\" title=\"table 2\">",
"      CHD likelihood with chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/21/19805\" title=\"table 3\">",
"      Risk death MI unstable angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?5/34/5665?source=related_link\" title=\"calculator 1\">",
"      Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for unstable angina or non ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20090?source=related_link\">",
"      Evaluation of chest pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/16/28938?source=related_link\">",
"      Evaluation of the adult with dyspnea in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/56/29578?source=related_link\">",
"      Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2746?source=related_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_13_31962="Therapeutic uses of recombinant coagulation factor VIIa";
var content_f31_13_31962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapeutic uses of recombinant coagulation factor VIIa",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/13/31962/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31962/contributors\">",
"     Maureane Hoffman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/13/31962/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31962/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/13/31962/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/13/31962/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/13/31962/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recombinant activated human factor VII produced by transfection of the human factor VII gene into cultured hamster cells is commercially available (Novo-Seven&reg;). Its FDA-approved indication in the United States is for promoting hemostasis in hemophiliacs with antibody inhibitors to coagulation factors VIII or IX. This product is currently licensed in Europe for the above indication as well as for treatment of congenital factor VII deficiency and Glanzmann's thrombasthenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link&amp;anchor=H18#H18\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Recombinant human factor VIIa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early in its development, recombinant FVIIa was investigated as a hemostatic agent in bleeding conditions other than hemophilia. Its apparent safety and utility in a variety of settings, most of which are not supported by clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/2-5\">",
"     2-5",
"    </a>",
"    ], has led to its use in less emergent conditions. It is in these \"off-label\" settings that most practitioners will encounter the use of rFVIIa.",
"   </p>",
"   <p>",
"    In this review, we will present an appraisal of the potential benefits, risks, and costs of recombinant human activated factor VIIa in non-hemophilic patients, while recognizing that very few high-quality studies are available to guide its use in these areas. The role of factor VII in coagulation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of hemostasis\", section on 'Extrinsic pathway'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hemophilia A or B who develop antibodies to the deficient factor (FVIII or FIX) can be difficult to manage. It is often not possible to neutralize high titer inhibitors even with administration of very high levels of replacement therapy. For this reason, in the past prothrombin complex concentrates (PCCs), partially purified and variably activated mixtures of the vitamin K-dependent clotting factors prepared from plasma, were utilized in such patients.",
"   </p>",
"   <p>",
"    PCCs can often \"bypass\" the need for the deficient factor and establish hemostasis in hemophiliacs with inhibitors. Newer products with increased levels of activated proteases (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/61/37844?source=see_link\">",
"     activated prothrombin complex concentrates",
"    </a>",
"    or aPCCs) were prepared in an attempt to increase the efficacy of bypassing therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. However, both PCCs and especially aPCCs were found to be associated with an increased risk of thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several contaminants in these products were considered as possible contributors to thrombogenicity: non-vitamin K-dependent zymogens, activated factors IX and X, and phospholipids from platelets resulting from inadequate centrifugation of the donor plasma. After numerous additional reports of thromboembolic complications, the International Society on Thrombosis and Hemostasis (ISTH) Scientific and Standardization Committee Thrombogenicity Registry was established in 1988 in order to determine which component(s) of these products were responsible for hemostatic efficacy and to develop more defined products, which might be more effective and safer.",
"   </p>",
"   <p>",
"    It had been hypothesized that FVIIa in aPCCs contributed significantly to hemostatic efficacy. Purified plasma-derived FVIIa (at doses of 5 to 20",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    was first used in the late 1980s as a bypassing agent in hemophiliacs with inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. While there was the concern that giving an activated clotting factor might be thrombogenic, this agent proved to be hemostatically effective for surgery and joint bleeding, without thrombotic complications or evidence of systemic activation of coagulation.",
"   </p>",
"   <p>",
"    Recombinant FVIIa (rFVIIa, NovoSeven), produced and developed as a commercial product by NovoNordisk, was shown to be effective as a bypassing agent in hemophiliacs with inhibitors and in acquired hemophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. It appeared to require doses up to 100",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    for efficacy, with no evidence of systemic activation of coagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose rFVIIa was originally thought to act by increasing the activity of the extrinsic tissue factor (TF)-associated coagulation pathway, as described in the following quote from an early review article: \"The concept of using FVIIa to induce hemostasis in hemophilia takes advantage of the normal",
"    <span class=\"nowrap\">",
"     TF/FVII-dependent",
"    </span>",
"    coagulation pathway which is enhanced by the administration of extra exogenous recombinant FVIIa\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the concentrations of rFVIIa required for hemostatic efficacy were far greater than would be required to saturate TF. This fact, combined with findings in experimental models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], has lent increasing support to the theory that rFVIIa does not exert its therapeutic effect through the TF pathway.",
"   </p>",
"   <p>",
"    Ordinarily, the activity of",
"    <span class=\"nowrap\">",
"     FVIIa/TF",
"    </span>",
"    at a site of injury is needed to initiate coagulation. However, when administered in doses sufficient to bypass the need for FVIII or FIX, rFVIIa binds to the surface of activated platelets in a TF-independent manner and promotes Factor X (FX) activation and thrombin generation where platelets are localized at a site of injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Binding of FVIIa to platelets appears to involve the glycoprotein",
"    <span class=\"nowrap\">",
"     Ib/IX/V",
"    </span>",
"    complex and anionic phospholipids expressed on activated platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. It has not been fully ruled out that TF-dependent activity might also contribute to the hemostatic effect of rFVIIa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the case of the hemophilias, platelet-bound rFVIIa partially restores platelet surface FX activation, which is deficient because of the absence of factor",
"    <span class=\"nowrap\">",
"     VIIIa/IXa",
"    </span>",
"    complexes. In non-hemophilic conditions, platelet-bound rFVIIa increases activation of both FIX and FX and increases thrombin generation above normal levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/29\">",
"     29",
"    </a>",
"    ]. Increased thrombin generation then promotes increased activation and local accumulation of platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/30\">",
"     30",
"    </a>",
"    ], including dysfunctional platelets, potentially improving hemostasis in a wide range of bleeding conditions.",
"   </p>",
"   <p>",
"    The above mechanism of action of rFVIIa has important implications for its clinical use(s):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since binding of rFVIIa to the platelet surface is a low-affinity interaction, it is not saturated at doses that are employed clinically. This means that increasing the dose (plasma concentration) of rFVIIa should increase the rate of platelet surface thrombin generation. Therefore, some practitioners have used doses of rFVIIa above the 90",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      recommended by the manufacturer and feel that this has resulted in increased hemostatic efficacy.",
"     </li>",
"     <li>",
"      Localization of rFVIIa activity to the activated platelet surface appears to explain the relative lack of thrombotic complications, since thrombin generation occurs on the appropriate surface (ie, activated platelets) and is subject to most of the normal control mechanisms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Conditions affecting rFVIIa activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proposed mechanism(s) of action for rFVIIa, as discussed above, suggests that the appropriate dose and effectiveness of rFVIIa may be quite different depending upon a number of other circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced levels of other coagulation factors and co-factors (eg, calcium, fibrinogen, prothrombin, factor X) as well as platelet number and function may limit the effectiveness of rFVIIa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/32-35\">",
"       32-35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Changes in body temperature and pH may reduce the activity of factor VIIa. As examples [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/36\">",
"       36",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      rFVIIa activity decreased by approximately 90 percent and tissue factor (TF)-rFVIIa complex activity decreased by approximately 60 percent when pH changed from 7.4 to 7.0. Thus, acidosis may markedly impair hemostatic function and reduce the response to rFVIIa.",
"     </li>",
"     <li>",
"      In marked contrast to the activity of the other coagulation proteases, rFVIIa activity did not decrease significantly when the temperature was decreased from 37&ordm; to 33&ordm; C. While overall hemostatic function is impaired by hypothermia, rFVIIa may be effective even in patients whose body temperature cannot be normalized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The half-life of rFVIIa in the circulation is 2 hours, shorter than that of normal factor VII (4 to 6 hours), as well as that of most of the other coagulation factors (",
"      <a class=\"graphic graphic_table graphicRef51595 \" href=\"mobipreview.htm?9/38/9836\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above-listed circumstances may limit the effectiveness of rFVIIa, especially in surgical and trauma patients, who may be suffering from the combination of hypothermia, acidosis, electrolyte disturbances, and loss of platelets and coagulation factors secondary to consumption or dilution by fluid administration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    massive transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=see_link&amp;anchor=H4#H4\">",
"     \"Massive blood transfusion\", section on 'Effects of acidosis and hypothermia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Factor VIIa analog",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recombinant activated factor VII analog (vatreptacog alfa (activated), NN1731) with enhanced activity is under active investigation. Vatreptacog alfa (activated) has three amino acid substitutions affecting the protease domain that stabilize the molecule in its active conformation without tissue factor, resulting in increased activity on the surface of activated platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/37-43\">",
"     37-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL UTILITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Approved indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Food and Drug Administration (FDA)-approved indications for rFVIIa include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment or prevention of bleeding in patients with hemophilia A or B who have inhibitors to factors VIII or IX, respectively",
"     </li>",
"     <li>",
"      Treatment or prevention of bleeding episodes in patients with acquired hemophilia",
"     </li>",
"     <li>",
"      Treatment or prevention of bleeding episodes in patients with congenital factor VII deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This product is currently licensed in Europe for bypassing inhibitors to factors VIII and IX in patients with hemophilia A and B, as well as for treatment of congenital factor VII deficiency and Glanzmann's thrombasthenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/44\">",
"     44",
"    </a>",
"    ]. While the efficacy of rFVIIa for these conditions is well established, the optimal dosing regimens are not. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link&amp;anchor=H18#H18\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Recombinant human factor VIIa'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16730?source=see_link&amp;anchor=H21#H21\">",
"     \"Rare (recessively inherited) coagulation disorders\", section on 'Factor VII deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=see_link&amp;anchor=H41#H41\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Recombinant factor VIIa'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hemophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    in patients with hemophilia and inhibitors is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link&amp;anchor=H18#H18\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Recombinant human factor VIIa'",
"    </a>",
"    ). However, certain salient aspects of its use in this setting will be reviewed here.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     Recombinant human factor VIIa",
"    </a>",
"    produces an excellent or effective response in over 90 percent of patients with hemophilia and inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Since licensure, the standard dosing has been considered to be 90 to 120",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    every 2 to 3 hours until cessation of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/45\">",
"     45",
"    </a>",
"    ]. However, dosing levels, intervals, and duration of treatment are subject to considerable variation among different medical centers.",
"   </p>",
"   <p>",
"    In order to overcome the logistic difficulties of repeated frequent bolus injections and, in an attempt to minimize usage, administration of rFVIIa by continuous infusion has been utilized. Treatment regimens combining an initial bolus dose with subsequent continuous infusion have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. While clearly more convenient, there is no evidence that continuous infusion uses less drug to control bleeding. Indeed, there is uncertainty as to whether the continuous infusion of rFVIIa is as therapeutically effective as an equivalent total dose administered via bolus injection.",
"   </p>",
"   <p>",
"    The proposed mechanism of action of rFVIIa suggests that intermittently attaining a high level of rFVIIa with bolus dosing will yield larger bursts of platelet-surface thrombin generation than will continuous maintenance of a lower plasma concentration. This has led some practitioners to advocate the use of higher, less frequent dosing of rFVIIa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/49\">",
"     49",
"    </a>",
"    ]. Accumulating anecdotal evidence suggests that this approach is at least as effective as standard dosing, but there is very little relevant high quality data to support this position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Glanzmann thrombasthenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Bernard-Soulier syndrome or Glanzmann thrombasthenia may become immunized to HLA antigens or the platelet glycoproteins,",
"    <span class=\"nowrap\">",
"     GPIb/IX/V",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa",
"    </span>",
"    respectively, and demonstrate refractoriness to transfusion with normal platelets. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37945?source=see_link&amp;anchor=H19#H19\">",
"     \"Refractoriness to platelet transfusion therapy\", section on 'Treatment of active bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=see_link&amp;anchor=H30#H30\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Glanzmann thrombasthenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of recombinant factor VIIa in the setting of platelet transfusion refractoriness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/50-56\">",
"     50-56",
"    </a>",
"    ], or prior to surgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/55,57,58\">",
"     55,57,58",
"    </a>",
"    ], has had anecdotal success in some, but not all patients. A suggested dose is 90 to 110",
"    <span class=\"nowrap\">",
"     mcg/kg,",
"    </span>",
"    repeated at 90-minute intervals as needed, although higher doses up to 270",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    have been used when the standard dose was not effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Off-label uses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant FVIIa has generated a great deal of interest and controversy as a potential \"general hemostatic agent\" to enhance hemostasis in patients with bleeding who may or may not have an underlying coagulation defect. Early in its development rFVIIa was reported to have a hemostatic effect in conditions other than hemophilia, including thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/59\">",
"     59",
"    </a>",
"    ], abnormalities of platelet function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/60\">",
"     60",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    over-anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enthusiasm for rFVIIa as a potential broad-spectrum hemostatic agent was ignited in 1999 by the dramatic case of a patient who became coagulopathic after suffering a gunshot wound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/62\">",
"     62",
"    </a>",
"    ]. All usual measures had failed to control his bleeding and rFVIIa was given as a last resort. The nearly miraculous recovery of this patient triggered an interest in the use of high-dose rFVIIa therapy in patients with a wide range of bleeding conditions who could not be managed by conventional therapy.",
"   </p>",
"   <p>",
"    Numerous case reports, series, and small clinical trials have, since that time, reported the effective use of rFVIIa in a wide range of conditions, including thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/63,64\">",
"     63,64",
"    </a>",
"    ], platelet functional defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/50\">",
"     50",
"    </a>",
"    ], hemorrhagic complications of hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/65\">",
"     65",
"    </a>",
"    ], and liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/66\">",
"     66",
"    </a>",
"    ]. Recombinant FVIIa has also been employed to overcome the hemostatic defect induced by a wide range of anticoagulants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/67\">",
"     67",
"    </a>",
"    ], including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/68,69\">",
"     68,69",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    and low molecular weight heparins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/70-72\">",
"     70-72",
"    </a>",
"    ], direct thrombin inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/73\">",
"     73",
"    </a>",
"    ], inhibitors of tissue factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/74\">",
"     74",
"    </a>",
"    ], and other antiplatelet agents, alone or in combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. Other studies have examined the utility of rFVIIa in preventing surgical hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/78\">",
"     78",
"    </a>",
"    ], treating trauma-associated hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/79\">",
"     79",
"    </a>",
"    ], and management of patients with massive uncontrolled bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The literature concerning the \"off-label\" use of rFVIIa is expanding so rapidly that it is hard to keep an accurate tally of the conditions in which it has been used. As an example, a retrospective analysis of data from the Premier Perspectives database, which contains discharge records from a sample of academic and nonacademic United States hospitals, has indicated that the use of rFVIIa increased more than 140-fold between 2000 and 2008, such that in 2008, 97 percent of 18,311 in-hospital uses were for off-label indications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/81\">",
"     81",
"    </a>",
"    ]. Accordingly, a registry has been developed to capture clinical experiences with the off-label use of this product in the management of severe bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of this off-label use was shown in a multi-institutional audit of 701 patients identified as having received rFVIIa; 92 percent were for \"off-label\" indications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/84\">",
"     84",
"    </a>",
"    ]. While there is overwhelming evidence that rFVIIa has hemostatic effects in non-hemophilic patients, many questions remain as to the appropriate settings and guidelines for use, risks of thrombotic complications, appropriate monitoring, dosing, and integration with transfusion therapy. In addition, information on the efficacy and side effects of rFVIIa in such settings is largely anecdotal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/84-87\">",
"     84-87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22768015\">",
"    <span class=\"h3\">",
"     Meta-analyses of off-label uses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of meta-analyses and a Cochrane review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/88\">",
"     88",
"    </a>",
"    ] have been performed concerning the off-label uses of rFVIIa.",
"   </p>",
"   <p>",
"    These issues were explored in a 2008 meta-analysis of 22 randomized controlled trials of rFVIIa in 3184 patients without hemophilia in which 15 percent died and 7.8 percent had thromboembolic events. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/89\">",
"     89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional blood transfusions were required in 41 percent. Those receiving rFVIIa were significantly less likely than those receiving placebo to require additional transfusions (OR 0.54; 95% CI 0.34-0.86).",
"     </li>",
"     <li>",
"      The use of rFVIIa, as compared with placebo, did not significantly decrease mortality (OR 0.88; 95% CI 0.71-1.1) nor did it significantly increase the incidence of thromboembolic events (OR 1.2; 95% CI 0.87-1.6).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent 2011 systematic review of 16 randomized controlled trials, 26 comparative observational studies, and 22 noncomparative observational studies reached the following conclusions concerning the benefits and harms of in-hospital use of rFVIIa for off-label indications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For five indications (intracranial hemorrhage, cardiac surgery, body trauma, brain trauma, liver transplantation) there was no evidence that the use of rFVIIa changed overall survival.",
"     </li>",
"     <li>",
"      For two of these five indications (intracranial hemorrhage, cardiac surgery) there was evidence for an increased risk of thromboembolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Regulatory concerns and costs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Off-label use of a drug, such as rFVIIa, for indications that are not FDA approved, is an acceptable practice providing that such uses are well-supported by high quality clinical data. Since the above-noted meta-analysis included ALL randomized controlled trials of off-label FVIIa use, it combined patients with a wide range of disorders, from hematopoietic cell transplantation to trauma to hemorrhagic stroke. Thus, a significant effect on outcome in one clinical setting could have been diluted by a lack of benefit in another.",
"   </p>",
"   <p>",
"    Similarly, an increased risk of thrombosis in one patient group (eg, hemorrhagic stroke in older patients with vascular disease) could have been hidden by the absence of increased risk in another group (eg, trauma in young previously healthy subjects). While this meta-analysis supports the overall contention that FVIIa can reduce bleeding in non-hemophilic patients, it cannot be viewed as high quality evidence for or against the efficacy or safety of FVIIa in any given patient group.",
"   </p>",
"   <p>",
"    In addition to the absence of high quality data concerning the efficacy and safety of off-label use of FVIIa, such use also has reimbursement and medicolegal implications that need to be considered by the clinician. A major factor influencing the use of rFVIIa is its high cost. A single dose of 90",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    to a 70 kg person costs at least $4500 in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/90\">",
"     90",
"    </a>",
"    ] and &pound;3700 in the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/91\">",
"     91",
"    </a>",
"    ]. However, in some highly selected clinical conditions, judicious short-term use of the drug may be cost-effective. Because of the high cost of rFVIIa, many institutions have policies specifying the acceptable circumstances for its off-label use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/91-93\">",
"     91-93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OFF-LABEL EXPERIENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In spite of the significant lack of data in many areas, rFVIIa is being used for a variety of off-label indications, including the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Congenital/acquired FVII deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of rFVIIa for preventing or treating bleeding in a patient with Factor VII deficiency, an indication for which rFVIIa is approved in Europe, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16730?source=see_link&amp;anchor=H21#H21\">",
"     \"Rare (recessively inherited) coagulation disorders\", section on 'Factor VII deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Factor XI deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with factor XI deficiency, considerably lower doses of rFVIIa than used in hemophiliacs with inhibitors appear to be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/14/37097?source=see_link&amp;anchor=H27#H27\">",
"     \"Factor XI deficiency\", section on 'Recombinant factor VIIa'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Von Willebrand disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the ability of FVIIa to enhance adhesion and function of Bernard-Soulier platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/29\">",
"     29",
"    </a>",
"    ], which lack the receptor for von Willebrand factor (VWF), it seems reasonable that FVIIa might also enhance platelet function when the ligand itself (ie, VWF) is deficient.",
"   </p>",
"   <p>",
"    Accordingly, Factor VIIa has been used in the treatment of patients with type 1, 2A, or 3 von Willebrand disease who have developed antibodies to VWF. This is a condition for which there are few treatment options and rFVIIa deserves consideration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21866?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of von Willebrand disease\", section on 'Recombinant Factor VIIa'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Inherited disorders of platelet function",
"    </span>",
"    &nbsp;&mdash;&nbsp;rFVIIa has been used to effectively manage bleeding (eg, nosebleeds, gingival bleeding, GI bleeds, childbirth, haemarthrosis, and",
"    <span class=\"nowrap\">",
"     surgery/invasive",
"    </span>",
"    procedures including dental extraction, catheter insertion, discectomy, hemicolectomy, duodenectomy and intestinal biopsy) in certain rare inherited disorders of platelet function (eg, Glanzmann thrombasthenia, Bernard-Soulier syndrome), when the presence of anti-platelet glycoprotein antibodies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-HLA antibodies makes platelet transfusion ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/50,82,83\">",
"     50,82,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37945?source=see_link&amp;anchor=H19#H19\">",
"     \"Refractoriness to platelet transfusion therapy\", section on 'Treatment of active bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=see_link&amp;anchor=H41#H41\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Recombinant factor VIIa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In subjects with inherited disorders of platelet function who are refractory to platelet transfusion, the recommended dose for treatment of bleeding episodes and for the prevention of bleeding in patients undergoing surgery or invasive procedures is 90 mcg (range: 80 to",
"    <span class=\"nowrap\">",
"     120)/kg",
"    </span>",
"    body weight at intervals of two hours (range: 1.5 to 2.5 hours). At least three doses should be administered to secure effective haemostasis. The recommended route of administration is bolus injection, since continuous infusion appears to be less effective. This indication is also approved in Europe and the data for efficacy are solid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Excessive warfarin-associated bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correction of the prothrombin time or the INR does not necessarily mean that the bleeding tendency following the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    has been reversed, since, as noted above, the PT test does not fully reflect the mechanism of action of rFVIIa in vivo (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Mechanism of action'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/68,69,98,99\">",
"     68,69,98,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accordingly, use of rFVIIa has been suggested in patients with excessive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -associated bleeding or for rapid reversal of anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=see_link&amp;anchor=H6#H6\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Recombinant factor VIIa'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Coagulopathy of liver dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that rFVIIa at doses ranging from 5 to 120",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    can improve the coagulopathy associated with severe liver dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/86,100-103\">",
"     86,100-103",
"    </a>",
"    ]. One small prospective study compared rFVIIa (40",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    plus plasma infusion to plasma infusion alone for correction of hemostatic function during placement of an intracranial pressure transducer element [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/104\">",
"     104",
"    </a>",
"    ]. The outcome was significantly better in the group receiving rFVIIa.",
"   </p>",
"   <p>",
"    In contrast, controlled trials have shown rFVIIa to be of no benefit in reducing transfusion in liver resection or transplantation, or controlling upper gastrointestinal bleeding in cirrhotic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/31,105-107\">",
"     31,105-107",
"    </a>",
"    ]. One might not expect rFVIIa to be useful in reducing hemorrhage in partial hepatectomy or transplantation, because transfusion rates have become quite low with the use of modern surgical techniques. Similarly, one might not expect variceal bleeding to respond to rFVIIa, since coagulopathy is not thought to play a significant role in this type of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31959?source=see_link&amp;anchor=H20#H20\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Liver failure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1928?source=see_link&amp;anchor=H5#H5\">",
"     \"General principles of the management of variceal hemorrhage\", section on 'Hemodynamic resuscitation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=see_link&amp;anchor=H166750581#H166750581\">",
"     \"Acute liver failure in adults: Management and prognosis\", section on 'Bleeding prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While rFVIIa is a potentially useful supplement to blood product therapy in liver disease, it is probably most useful when bleeding is thought to be due to a coagulopathy. Two factors support its use in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In many cases the volume of plasma required to maintain coagulation factors at hemostatic levels (ie, 10 to 15",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      is not tolerated well by patients with significant liver disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical use of plasma components\", section on 'Dose and indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Factor VII has the shortest half-life of the procoagulant factors synthesized in the liver (",
"      <a class=\"graphic graphic_table graphicRef51595 \" href=\"mobipreview.htm?9/38/9836\">",
"       table 1",
"      </a>",
"      ), and may also be at lower concentrations than the other circulating factors when liver function is impaired. The half-life of activated factor VIIa is even shorter (less than three hours), as attested to its requirement for dosing every two to three hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, it seems well founded to supplement plasma infusion with low doses of rFVIIa (&lt;40",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    as a means of maintaining hemostatic levels of FVII with a reduced volume load. As in the case of patients being treated with vitamin K antagonists, PT and aPTT values or ratios do not give a reliable estimate of bleeding risk in this setting and do not accurately reflect the effect of rFVIIa on hemostatic function in patients with liver disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24022?source=see_link&amp;anchor=H5#H5\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\", section on 'Coagulation factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33914?source=see_link&amp;anchor=H5858486#H5858486\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Therapeutic agents for bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute intracerebral hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of rFVIIa in acute intracerebral hemorrhage not associated with the use of oral vitamin K antagonists is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32650?source=see_link&amp;anchor=H22#H22\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Hemostatic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Reduction of perioperative blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following trauma or surgery, patients may develop a coagulopathy that is manifest as uncontrollable microvascular bleeding. This is generally managed by careful attention to controlling hypothermia and acidosis and with blood component transfusion. Recombinant FVIIa has generally been used to control microvascular bleeding when conventional therapy has failed. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Conditions affecting rFVIIa activity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=see_link&amp;anchor=H4#H4\">",
"     \"Massive blood transfusion\", section on 'Effects of acidosis and hypothermia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first prospective controlled trial of rFVIIa for perioperative bleeding was not to control coagulopathic bleeding, but rather to",
"      <span class=\"nowrap\">",
"       prevent/reduce",
"      </span>",
"      bleeding in patients undergoing retropubic prostatectomy. An IV bolus dose of 20 to 40",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      reduced blood loss and the need for transfusion in the perioperative period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/78\">",
"       78",
"      </a>",
"      ]. While this study was not a model for the cost-effective use of this agent, it demonstrated its safety in non-hemophilic patients.",
"     </li>",
"     <li>",
"      The efficacy and safety of rFVIIa were studied in a placebo-controlled, randomized, dose-escalation trial in 68 patients who had undergone cardiac surgery and were bleeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/110\">",
"       110",
"      </a>",
"      ]. Significantly fewer patients in the two rFVIIa-treated groups (40 or 80",
"      <span class=\"nowrap\">",
"       mcg/kg)",
"      </span>",
"      underwent reoperation as a result of bleeding or required allogeneic transfusion. However, there were more critical serious adverse events in the rFVIIa-treated groups (ie, death, cerebral infarction, other thromboembolic events), although these differences did not reach statistical significance (placebo: 7 percent; 40",
"      <span class=\"nowrap\">",
"       mcg/kg:",
"      </span>",
"      14 percent, 80",
"      <span class=\"nowrap\">",
"       mcg/kg:",
"      </span>",
"      12 percent; odds ratio 1.67; 95% CI 0.50-5.47).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A wide range of doses has been used for controlling coagulopathic bleeding. Recombinant FVIIa has been used to control intractable hemorrhage in patients undergoing cardiac surgery (dose range 13 to 111",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    when the bleeding could not be managed by transfusion therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. It appears that lower dose therapy (40",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    is effective in many surgical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/111,113\">",
"     111,113",
"    </a>",
"    ]. However, a retrospective study in 25 children undergoing cardiac surgery with cardiopulmonary bypass indicated control of excessive postoperative bleeding with no adverse complications following one or two infusions of recombinant FVIIa at a dose of 180",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FVIIa is also an option when a surgical patient declines blood products, as in the case of Jehovah's Witness patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/115-118\">",
"     115-118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10986?source=see_link\">",
"     \"The approach to the patient who refuses blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When used to control perioperative bleeding, such as in patients with refractory bleeding after acute aortic dissection surgery, rFVIIa is generally used after conventional transfusion and anti-fibrinolytic therapy have failed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/119\">",
"     119",
"    </a>",
"    ]. There is no high quality evidence on these points, but it appears that the patients who are most likely to benefit from rFVIIa are those with a significant coagulopathy. In one study and one comprehensive review, the sooner rFVIIa was given to such patients, the better was the outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/113,120\">",
"     113,120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of seven randomized controlled studies of the safety and efficacy of rFVIIa in major surgical procedures reached the following conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/121\">",
"     121",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Efficacy",
"      </strong>",
"      &mdash; Treatment with rFVIIa was associated with a reduced risk of receiving allogeneic packed red cell transfusion (Odds Ratio (OR) 0.29; 95% CI 0.10-0.80).",
"     </li>",
"     <li>",
"      <strong>",
"       Safety",
"      </strong>",
"      &mdash; No significant differences in thromboembolic complications or mortality rate were seen between the rFVIIa and placebo treatment groups, although the total number of events was small for both safety endpoints.",
"     </li>",
"     <li>",
"      <strong>",
"       Dosing",
"      </strong>",
"      &mdash; In a subgroup analysis, only patients receiving rFVIIa in a dose of at least 50",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      of rFVIIa had a significant treatment benefit (OR 0.43; 95% CI 0.23-0.78).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors estimated that the cost-benefit ratio for the use of rFVIIa would be favorable ONLY if each transfused patient was expected to receive 40 units of packed red cells (ie, approximately 4 total blood volumes replaced per patient).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Managing post-traumatic hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many case reports and small series document the use of rFVIIa to control coagulopathic bleeding in trauma patients. This is an exceptionally difficult patient population in which to conduct controlled clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/122\">",
"     122",
"    </a>",
"    ]. In addition to informed consent concerns in an acutely injured population, trauma patients are unavoidably a heterogeneous group.",
"   </p>",
"   <p>",
"    Two linked randomized, multi-center controlled trials of the use of rFVIIa for this indication have thus far been completed as planned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/79,123\">",
"     79,123",
"    </a>",
"    ]. One trial enrolled 143 bleeding patients with severe blunt trauma and the other enrolled 134 bleeding patients with penetrating trauma. Patients were enrolled after they had been transfused with six units of blood within four hours of admission. Patients assigned to receive rFVIIa received three doses of drug (200, 100 and 100",
"    <span class=\"nowrap\">",
"     mcg/kg).",
"    </span>",
"    The first dose was given after the eighth unit of red cells and the two subsequent doses were one and three hours later. There was a statistically significant reduction in red blood cell transfusion and the need for massive (&gt;20 unit) transfusion in blunt trauma patients treated with rFVIIa. There was a similar trend in the penetrating trauma group. There were no differences in adverse events, such as thromboembolism or mortality, between the treatment groups in either study.",
"   </p>",
"   <p>",
"    These studies have been criticized on several counts and interpreted as showing no benefit of rFVIIa, since there was no difference in overall mortality. However, this author believes these studies are more appropriately viewed as the first step in identifying patient groups that might benefit from rFVIIa. Furthermore, they demonstrated that trauma patients, who could be considered in a potentially prothrombotic state due to extensive tissue damage, can be given rFVIIa without excessive risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. Since the trauma patients were primarily young males, the same low risk of complications might not apply to older patients with preexisting risk factors for thrombosis (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Safety issues'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The blunt trauma patients may have derived more benefit from rFVIIa because they were more likely to have coagulopathic bleeding responsive to rFVIIa, while the penetrating trauma patients were more likely to be bleeding from damage to large blood vessels, which is unlikely to be responsive to rFVIIa, unless also accompanied by coagulopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/124,126\">",
"     124,126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety and cost-effectiveness of rFVIIa were evaluated in a retrospective study of coagulopathic patients with relatively isolated traumatic brain injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/127\">",
"     127",
"    </a>",
"    ]. Of the 179 patients, 62 percent were treated conventionally and 38 percent with rFVIIa. There were no differences in mortality or thromboembolic complications between the two groups, although for the subgroup of 110 patients requiring admission to the intensive care unit, hospital length of stay, days of mechanical ventilation, plasma utilization, and total costs were lower for rFVIIa treated patients. Other studies of the use of rFVIIa in patients with traumatic intracranial hemorrhage have reported results varying from beneficial to harmful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main conclusions that can be drawn concerning the utility of rFVIIa in bleeding, coagulopathic trauma patients are that this agent shows significant potential and appears to be safe in young, previously healthy individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/129-131\">",
"     129-131",
"    </a>",
"    ]. The issue of which patients with severe trauma are most likely to benefit from treatment with rFVIIa was approached in a retrospective analysis of 380 injured patients who received this agent as an adjunct for hemorrhage control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/132\">",
"     132",
"    </a>",
"    ]. Logistic regression analysis indicated that systolic blood pressure &gt;90 mm Hg, platelet count",
"    <span class=\"nowrap\">",
"     &gt;100,000/microL,",
"    </span>",
"    and a blood pH &ge;7.2 were associated with significantly improved survival for this group of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=see_link&amp;anchor=H3#H3\">",
"     \"Massive blood transfusion\", section on 'Alterations in the coagulation system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Therapy with GPIIb/IIIa antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of rFVIIa in treating a congenital deficiency or defect in platelet",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa",
"    </span>",
"    (ie, Glanzmann thrombasthenia) suggests that it might also be useful for treating bleeding during anti-platelet therapy with",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa",
"    </span>",
"    antagonists, a condition which can be difficult to manage with platelet transfusions alone. There are in vitro data to support this suggestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/19\">",
"     19",
"    </a>",
"    ], but no clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pulmonary hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are anecdotal reports of the successful use of rFVIIa in patients with pulmonary hemorrhage (eg, diffuse alveolar hemorrhage or massive hemoptysis) following a variety of insults, including pneumonia, hematopoietic cell transplant, metastatic choriocarcinoma, and microscopic polyangiitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/133-137\">",
"     133-137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24228136\">",
"    <span class=\"h2\">",
"     Off-label use in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The off-label use of rFVIIa in children has also been expanding, despite the absence of adequate clinical trials demonstrating safety and efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/138\">",
"     138",
"    </a>",
"    ]. In an analysis using the Pediatric Health Information System administrative database, of the 4942 admissions in which rFVIIa was used in children 18 years of age or younger between 2000 and 2007, 74 percent were for off-label uses. The mortality in the off-label group was 34 percent; thrombotic events occurred in 10.9 percent of the off-label admissions.",
"   </p>",
"   <p>",
"    A separate analysis from the Haemostasis Registry Steering Committee reported on the off-label use of rFVIIa in 388 pediatric patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/139\">",
"     139",
"    </a>",
"    ]. The median age was 12 months and median first dose was 114",
"    <span class=\"nowrap\">",
"     mcg/kg.",
"    </span>",
"    There was a reduction in administration of blood products in the 24 hours after the first dose of FVIIa. Thromboembolic adverse events were reported in 5.4 percent, with no association between the thrombotic event and the size of the first dose. Overall 28-day mortality was 27 percent. On multivariate analysis, low pre-administration pH values and use in a non-surgical setting were both significantly associated with a worse outcome. While these registry data suggest that rFVIIa may be effective as a hemostatic agent in pediatric patients, they do not provide useful data on appropriate dosing, true complication rates, or expected outcomes.",
"   </p>",
"   <p>",
"    A review of the off-label use of rFVIIa in pediatric cardiac surgery patients has concluded that there is no substantive evidence to support the efficacy of this agent as prophylactic or routine therapy during pediatric cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/140\">",
"     140",
"    </a>",
"    ]. They further concluded that use of this agent as rescue therapy for massive, life-threatening, refractory bleeding needs to take into account the possibility of thrombotic complications following its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DOSING AND LABORATORY MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently no means of determining the optimal dose and dosing regimen of rFVIIa for a given individual or a given condition, and clinical practices vary widely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/91\">",
"     91",
"    </a>",
"    ]. Since there is no laboratory test that correlates well with the clinical efficacy of rFVIIa, dosing must be determined empirically. However, the use (especially off-label use) of rFVIIa could be made much more rational if a test could be devised and validated that would measure or predict the rFVIIa dose and circulating level needed for achieving effective hemostasis.",
"   </p>",
"   <p>",
"    Such a test would presumably include both the patient's platelets and plasma, since rFVIIa acts on the platelet surface and both coagulation factor levels and platelet attributes have been shown to affect the degree to which a given level of rFVIIa boosts thrombin generation on the platelet surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/20,141,142\">",
"     20,141,142",
"    </a>",
"    ]. While there are currently several whole blood coagulation tests on the market, it remains to be seen whether any of them will be useful in monitoring rFVIIa therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SAFETY ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;While significant concern over the possibility of inciting thrombosis accompanied the initial use of rFVIIa, its subsequent safety record in treating hemophiliacs with inhibitors is impressive, with doses of up to 346",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    being well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/143\">",
"     143",
"    </a>",
"    ]. Available clinical evidence suggests that the isolated thrombotic events associated with its use in approved indications occur primarily in subjects with pre-existing risk factors for thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Thromboembolic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall reported incidence of thromboembolic complications following use of rFVIIa has ranged from a low of 1 to 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/92,107\">",
"     92,107",
"    </a>",
"    ] to as high as 9.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/84,144\">",
"     84,144",
"    </a>",
"    ]. Most of these complications have been associated with off-label use. This was shown in two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of adverse events reported to the US FDA, in which there were 168 reports describing 185 thromboembolic events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/145\">",
"       145",
"      </a>",
"      ], unlabeled indications accounted for 151 (90 percent) of the reports. Events included thromboembolic cerebrovascular accidents, acute myocardial infarction, arterial thrombosis, pulmonary embolus, venous thrombosis, including deep vein thrombosis, and clotted access devices. In 36 of the 50 reported deaths, the probable cause of death was the thromboembolic event.",
"     </li>",
"     <li>",
"      In a review of data from 35 randomized, placebo-controlled trials of rFVIIa used on an off-label basis, there were 498 thromboembolic events among 4468 subjects (11.1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/146\">",
"       146",
"      </a>",
"      ]. While rates of venous thromboembolic events were similar (5.3 percent for rFVIIa and 5.7 percent for placebo), rates of arterial thromboembolic events were significantly higher in those receiving rFVIIa (5.5 versus 3.2 percent). Rates of arterial events were especially high among subjects 75 years of age or older (10.8 percent) as compared with those &lt;75 years of age (4.1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A multicenter assessment of the off-label use of rFVIIa in 315 subjects found that 9.8 percent of patients suffered an adverse event within 24 hours of rFVIIa administration, most of which were thrombotic in nature and none of which was fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/84\">",
"     84",
"    </a>",
"    ]. Thrombosis was associated with a higher cumulative dose of rFVIIa. A significant proportion of patients who received rFVIIa for off-label indications (21 percent) had risk factors for thrombosis before rFVIIa administration including: recent or active thromboembolic events, disseminated intravascular coagulation, heart failure, diabetes, smoking, inflammatory bowel disease, malignancy, nephrotic syndrome, hyperlipidemia, history of coronary artery disease, ischemic stroke, deep venous thrombosis, pulmonary embolism, or Budd-Chiari syndrome. Thus, patients who receive rFVIIa for off-label indications have very different hemostatic and vascular characteristics that put them at greater risk for thrombosis than the hemophilics for whom we have extensive safety data.",
"   </p>",
"   <p>",
"    In a review of 13 clinical trials using rFVIIa for coagulopathy secondary to treatment with anticoagulants, cirrhosis, or severe traumatic injury, adverse thrombotic events were noted in 5.3 percent of those treated with placebo and 6.0 percent of those receiving rFVIIa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is one group of patients who are much more homogeneous from which we can draw some limited conclusions about the thrombotic risk of rFVIIa administration. These are patients who received rFVIIa for treatment of spontaneous intracerebral hemorrhage (ICH). While these patients had some degree of underlying vascular disease, they likely had normal hemostatic function or even a procoagulant state at the time of rFVIIa administration. In the initial clinical trial, 399 patients with spontaneous ICH who could be evaluated within three hours of onset were assigned to received placebo, 40, 80 or 160",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    of rFVIIa; patients with a recent history of thromboembolic or vaso-occlusive disease were excluded from the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this trial, the risk of arterial thrombosis appeared to show a dose dependence. A similar result was seen in the subsequent placebo-controlled, randomized FAST trial, which evaluated efficacy and safety of rFVIIa (zero, 20, or 80",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    in a similar patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/148\">",
"     148",
"    </a>",
"    ]. While the overall frequency of serious thromboembolic events was similar in the three patient groups (8, 9, and 10 percent, respectively), the frequency of arterial events was significantly higher in the group receiving the 80",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    dose of rFVIIa (8.5 percent) when compared with that in the placebo-treated group (4.2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provisional conclusions from the available clinical and laboratory data concerning the risk of thrombosis following the use of rFVIIa include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hemophilia or a similarly profound impairment of hemostatic function have a very low risk of significant thrombosis associated with rFVIIa administration and can tolerate extremely high doses.",
"     </li>",
"     <li>",
"      Patients with profoundly impaired hemostasis can occasionally experience thrombosis when hemostatic function is improved by FVIIa administration, especially if they have pre-existing risk factors for thrombosis.",
"     </li>",
"     <li>",
"      The risk of thrombosis associated with rFVIIa administration is greatest in patients with the least impaired hemostatic function and the most thrombotic risk factors, such as underlying vascular disease or direct vascular injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/149\">",
"       149",
"      </a>",
"      ]. This conclusion is supported by the finding that a given level of rFVIIa boosts platelet-surface thrombin generation to a much greater extent in the presence of normal levels of coagulation factors than under hemophilic conditions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Approved indications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, the only FDA-approved indication for recombinant Factor VIIa (rFVIIa) is for bypassing inhibitors to factors VIII and IX in patients with hemophilia A and B, respectively. This subject is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link&amp;anchor=H18#H18\">",
"       \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Recombinant human factor VIIa'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In European countries, rFVIIa is licensed for the above indications as well as for treatment of congenital factor VII deficiency and Glanzmann's thrombasthenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/13/31962/abstract/105\">",
"       105",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16730?source=see_link&amp;anchor=H21#H21\">",
"       \"Rare (recessively inherited) coagulation disorders\", section on 'Factor VII deficiency'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=see_link&amp;anchor=H41#H41\">",
"       \"Congenital and acquired disorders of platelet function\", section on 'Recombinant factor VIIa'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Off-label uses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant FVIIa has been useful in the management of some non-hemophilic patients with intractable bleeding, but the optimal dose and schedule are not known with certainty. Since efficacy and thrombotic risk associated with the use of rFVIIa do not always increase in parallel, the dose schedule that maximizes efficacy while minimizing thrombotic risk has generally been determined empirically for different categories of patients.",
"   </p>",
"   <p>",
"    Disorders in which anecdotal success following the use of rFVIIa has been reported are summarized above (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Off-label uses'",
"    </a>",
"    above). In the absence of high-quality data favoring off-label use of this agent, the absence of a laboratory test able to predict response to this agent, and considering the high cost of rFVIIa, we suggest that off-label use of recombinant factor VIIa be considered only when hemorrhage has not responded to transfusion or other conventional therapy (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). Appropriate uses would include patients who are currently experiencing, or are likely to experience, life-threatening bleeding and meet one or more of the following additional criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No response to, or inability to tolerate, conventional therapy",
"     </li>",
"     <li>",
"      Appropriate blood products (eg, compatible red cells) are unavailable or are refused by the patient",
"     </li>",
"     <li>",
"      Presence of coagulopathic bleeding",
"     </li>",
"     <li>",
"      Bleeding conditions for which no other therapy is available",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the appropriate dose of recombinant factor VIIa to be given under such circumstances is not known, it should be proportionate to the degree of hemostatic impairment and be given before hypothermia and acidosis impair effectiveness of the coagulation system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=see_link&amp;anchor=H4#H4\">",
"     \"Massive blood transfusion\", section on 'Effects of acidosis and hypothermia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, in a patient who is truly coagulopathic and the degree of impairment is severe, an initial dose of 90",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    would seem appropriate. However, few &ldquo;off-label&rdquo; uses will present the degree of impairment seen in hemophilia and a lower dose should be considered.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/1\">",
"      Kessler C. Haemostasis.com: clinical experiences in the investigational use of rFVIIa in the management of severe haemorrhage. Br J Haematol 2004; 127:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/2\">",
"      Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2007; :CD005011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/3\">",
"      Cosmi B. Review: recombinant factor VIIa does not differ from placebo for prevention or treatment of bleeding in patients without hemophilia. ACP J Club 2007; 147:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/4\">",
"      Lin Y, Stanworth S, Birchall J, et al. Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis. CMAJ 2011; 183:E9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/5\">",
"      Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011; 154:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/6\">",
"      Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/7\">",
"      Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/8\">",
"      Lusher JM, Blatt PM, Penner JA, et al. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/9\">",
"      Kasper CK. Postoperative thromboses in hemophilia B. N Engl J Med 1973; 289:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/10\">",
"      Hedner U, Bjoern S, Bernvil SS, et al. Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis 1989; 19:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/11\">",
"      Hedner U, Glazer S, Pingel K, et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/12\">",
"      Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993; 7:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/13\">",
"      Hedner U. Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost 2000; 26:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/14\">",
"      Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/15\">",
"      O'Connell N, Mc Mahon C, Smith J, et al. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors. Br J Haematol 2002; 116:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/16\">",
"      Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/17\">",
"      Hedner U. Dosing and monitoring NovoSeven treatment. Haemostasis 1996; 26 Suppl 1:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/18\">",
"      Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/19\">",
"      Lisman T, Adelmeijer J, Heijnen HF, de Groot PG. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/20\">",
"      Hoffman M, Monroe DM 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 Suppl 1:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/21\">",
"      Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 2003; 17 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/22\">",
"      Lisman T, Adelmeijer J, Cauwenberghs S, et al. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 2005; 3:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/23\">",
"      Weeterings C, de Groot PG, Adelmeijer J, Lisman T. The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood 2008; 112:3227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/24\">",
"      Hoffman M. FVIIa: you've come a long way, baby! Blood 2008; 112:3002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/25\">",
"      Butenas S, Brummel KE, Branda RF, et al. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/26\">",
"      Butenas S, Brummel KE, Bouchard BA, Mann KG. How factor VIIa works in hemophilia. J Thromb Haemost 2003; 1:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/27\">",
"      Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/28\">",
"      Shibeko AM, Woodle SA, Lee TK, Ovanesov MV. Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood 2012; 120:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/29\">",
"      Monroe DM, Hoffman M, Allen GA, Roberts HR. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost 2000; 26:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/30\">",
"      Gal&aacute;n AM, Tonda R, Altisent C, et al. Recombinant factor VIIa (Novoseven) restores deficient coagulation: experience from an ex vivo model. Semin Hematol 2001; 38:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/31\">",
"      Al-Ruzzeh S, Navia JL. The \"off-label\" role of recombinant factor VIIa in surgery: is the problem deficient evidence or defective concept? J Am Coll Surg 2009; 209:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/32\">",
"      Allen GA, Hoffman M, Roberts HR, Monroe DM. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. Br J Haematol 2006; 134:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/33\">",
"      Allen GA, Monroe DM 3rd, Roberts HR, Hoffman M. The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation. Blood Coagul Fibrinolysis 2000; 11 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/34\">",
"      Martinowitz U, Michaelson M, Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 3:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/35\">",
"      Lewis NR, Brunker P, Lemire SJ, Kaufman RM. Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage. Transfusion 2009; 49:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/36\">",
"      Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/37\">",
"      Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci U S A 2001; 98:13583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/38\">",
"      M&oslash;ss J, Scharling B, Ezban M, M&oslash;ller S&oslash;rensen T. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost 2009; 7:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/39\">",
"      Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost 2009; 7:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/40\">",
"      Holmberg HL, Lauritzen B, Tranholm M, Ezban M. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. J Thromb Haemost 2009; 7:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/41\">",
"      Levy JH, Levi M. A modified recombinant factor VIIa: can we make it work harder, better, faster, stronger? J Thromb Haemost 2009; 7:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/42\">",
"      Hoffman M, Volovyk Z, Persson E, et al. Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. J Thromb Haemost 2011; 9:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/43\">",
"      de Paula EV, Kavakli K, Mahlangu J, et al. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost 2012; 10:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/44\">",
"      Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 7:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/45\">",
"      Rodriguez-Merchan EC, Rocino A, Ewenstein B, et al. Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia 2004; 10 Suppl 2:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/46\">",
"      Santagostino E, Morfini M, Rocino A, et al. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/47\">",
"      Ludlam CA, Smith MP, Morfini M, et al. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/48\">",
"      Smith MP, Ludlam CA, Collins PW, et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost 2001; 86:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/49\">",
"      Hedner U. Recombinant factor VIIa (Novoseven) as a hemostatic agent. Semin Hematol 2001; 38:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/50\">",
"      Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94:3951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/51\">",
"      d'Oiron R, M&eacute;nart C, Trzeciak MC, et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/52\">",
"      Patel RK, Savidge GF, Rangarajan S. Use of recombinant factor VIIa for post-operative haemorrhage in a patient with Glanzmann's thrombasthenia and human leucocyte antigen antibodies. Br J Haematol 2001; 114:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/53\">",
"      Martin I, Kriaa F, Proulle V, et al. Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb-IIIa antibodies. Br J Haematol 2002; 119:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/54\">",
"      Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104:3858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/55\">",
"      Bolton-Maggs PH, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/56\">",
"      Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost 1999; 82:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/57\">",
"      Poon MC, D'Oiron R, Von Depka M, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004; 2:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/58\">",
"      Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003; 121:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/59\">",
"      Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26 Suppl 1:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/60\">",
"      Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/61\">",
"      Diness V, Lund-Hansen T, Hedner U. Effect of recombinant human FVIIA on warfarin-induced bleeding in rats. Thromb Res 1990; 59:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/62\">",
"      Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/63\">",
"      Kjalke M, Johannessen M, Hedner U. Effect of recombinant factor VIIa (Novoseven) on thrombocytopenia-like conditions in vitro. Semin Hematol 2001; 38:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/64\">",
"      Al Hammadi AM, Sallah S. Efficacy and safety of recombinant factor VIIa in the treatment of bleeding episodes in patients with aplastic anemia. J Thromb Haemost 2007; 5:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/65\">",
"      Blatt J, Gold SH, Wiley JM, et al. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001; 28:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/66\">",
"      Hendriks HG, Meijer K, de Wolf JT, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001; 71:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/67\">",
"      Levi M, Bijsterveld NR, Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Semin Hematol 2004; 41:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/68\">",
"      Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/69\">",
"      Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005; 2:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/70\">",
"      Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/71\">",
"      Chan S, Kong M, Minning DM, et al. Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin. J Thromb Haemost 2003; 1:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/72\">",
"      Firozvi K, Deveras RA, Kessler CM. Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. Am J Hematol 2006; 81:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/73\">",
"      Oh JJ, Akers WS, Lewis D, et al. Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin. Pharmacotherapy 2006; 26:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/74\">",
"      Friederich PW, Levi M, Bauer KA, et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001; 103:2555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/75\">",
"      Ng HJ, Koh LP, Lee LH. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 2003; 82:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/76\">",
"      Altman R, Scazziota A, DE Lourdes Herrera M, Gonzalez C. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost 2006; 4:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/77\">",
"      Cherfan A, Arabi Y, Al Askar A, Al Shimemeri A. Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. Pharmacotherapy 2007; 27:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/78\">",
"      Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/79\">",
"      Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/80\">",
"      Berkhof FF, Eikenboom JC. Efficacy of recombinant activated Factor VII in patients with massive uncontrolled bleeding: a retrospective observational analysis. Transfusion 2009; 49:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/81\">",
"      Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med 2011; 154:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/82\">",
"      Poon MC, d'Oiron R. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrinolysis 2000; 11 Suppl 1:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/83\">",
"      Poon MC, Zotz R, Di Minno G, et al. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol 2006; 43:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/84\">",
"      MacLaren R, Weber LA, Brake H, et al. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion 2005; 45:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/85\">",
"      Mathew P. The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. A systematic review. Thromb Haemost 2004; 92:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/86\">",
"      Roberts HR, Monroe DM 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/87\">",
"      Willis CD, Cameron PA, Phillips LE. Clinical guidelines and off-license recombinant activated factor VII: content, use, and association with patient outcomes. J Thromb Haemost 2009; 7:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/88\">",
"      Simpson E, Lin Y, Stanworth S, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2012; 3:CD005011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/89\">",
"      Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg 2008; 248:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/90\">",
"      Levi M, Peters M, B&uuml;ller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/91\">",
"      Biss TT, Hanley JP. Use of recombinant factor VIIa (rFVIIa) in the management of intractable haemorrhage: a survey of current UK practice. Br J Haematol 2007; 138:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/92\">",
"      Goodnough LT, Lublin DM, Zhang L, et al. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/93\">",
"      Mathew P, Simon TL, Hunt KE, Crookston KP. How we manage requests for recombinant factor VIIa (NovoSeven). Transfusion 2007; 47:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/94\">",
"      Schulman S, N&eacute;meth G. An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. Haemophilia 2006; 12:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/95\">",
"      Basso IN, Keeling D. Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. Blood Coagul Fibrinolysis 2004; 15:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/96\">",
"      Ciavarella N, Schiavoni M, Valenzano E, et al. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis 1996; 26 Suppl 1:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/97\">",
"      Tarantino MD, Aberle R. Recombinant factor VIIa (NovoSeven) for post-prostatectomy hemorrhage in a patient with type I von Willebrand disease. Am J Hematol 2001; 68:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/98\">",
"      Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med Sci Monit 2002; 8:CS98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/99\">",
"      Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/100\">",
"      Chuansumrit A, Treepongkaruna S, Phuapradit P. Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost 2001; 85:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/101\">",
"      Ramsey G. Treating coagulopathy in liver disease with plasma transfusions or recombinant factor VIIa: an evidence-based review. Best Pract Res Clin Haematol 2006; 19:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/102\">",
"      Atkison PR, Jardine L, Williams S, et al. Use of recombinant factor VIIa in pediatric patients with liver failure and severe coagulopathy. Transplant Proc 2005; 37:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/103\">",
"      Quan DJ, Bass NM, Hirose R. The effect of recombinant factor VIIA and fresh frozen plasma on the INR in patients with acute and chronic liver failure. Hepatology 2003; 38:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/104\">",
"      Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003; 9:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/105\">",
"      Lodge JP, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/106\">",
"      Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005; 102:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/107\">",
"      Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/108\">",
"      Jimenez-Saenz M, Romero-Castro R, Pellicer-Bautista FJ, Herrerias-Gutierrez JM. Recombinant factor VIIa for variceal bleeding: when, why, and how? Gastroenterology 2005; 128:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/109\">",
"      Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/110\">",
"      Gill R, Herbertson M, Vuylsteke A, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009; 120:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/111\">",
"      van de Garde EM, Bras LJ, Heijmen RH, et al. Low-dose recombinant factor VIIa in the management of uncontrolled postoperative hemorrhage in cardiac surgery patients. J Cardiothorac Vasc Anesth 2006; 20:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/112\">",
"      Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005; 45:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/113\">",
"      Tawfick WA, Tawfik S, Hynes N, et al. Critical bleeding in vascular surgery: expanding the indication of recombinant activated factor VII. Vascular 2006; 14:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/114\">",
"      Kylasam S, Mos K, Fijtin S, et al. Recombinant activated factor VII following pediatric cardiac surgery. J Intensive Care Med 2009; 24:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/115\">",
"      Waddington DP, McAuley FT, Hanley JP, Summerfield GP. The use of recombinant factor viia in a jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage. Br J Haematol 2002; 119:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/116\">",
"      Jabbour N, Gagandeep S, Peilin AC, et al. Recombinant human coagulation factor VIIa in Jehovah's Witness patients undergoing liver transplantation. Am Surg 2005; 71:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/117\">",
"      Haan J, Scalea T. A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. Am Surg 2005; 71:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/118\">",
"      Tanaka KA, Waly AA, Cooper WA, Levy JH. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 2003; 98:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/119\">",
"      Tritapepe L, De Santis V, Vitale D, et al. Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis. Crit Care Med 2007; 35:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/120\">",
"      Karkouti K, Beattie WS, Arellano R, et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation 2008; 118:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/121\">",
"      Ranucci M, Isgr&ograve; G, Soro G, et al. Efficacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Arch Surg 2008; 143:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/122\">",
"      Hauser CJ, Boffard K, Dutton R, et al. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma 2010; 69:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/123\">",
"      Rizoli SB, Boffard KD, Riou B, et al. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials. Crit Care 2006; 10:R178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/124\">",
"      Wade CE, Eastridge BJ, Jones JA, et al. Use of recombinant factor VIIa in US military casualties for a five-year period. J Trauma 2010; 69:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/125\">",
"      Dutton RP, Parr M, Tortella BJ, et al. Recombinant activated factor VII safety in trauma patients: results from the CONTROL trial. J Trauma 2011; 71:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/126\">",
"      Fox CJ, Mehta SG, Cox ED, et al. Effect of recombinant factor VIIa as an adjunctive therapy in damage control for wartime vascular injuries: a case control study. J Trauma 2009; 66:S112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/127\">",
"      Stein DM, Dutton RP, Kramer ME, Scalea TM. Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. J Trauma 2009; 66:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/128\">",
"      DeLoughery EP, Lenfesty B, DeLoughery TG. A retrospective case control study of recombinant factor VIIa in patients with intracranial haemorrhage caused by trauma. Br J Haematol 2011; 152:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/129\">",
"      Harrison TD, Laskosky J, Jazaeri O, et al. \"Low-dose\" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. J Trauma 2005; 59:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/130\">",
"      Bauz&aacute; G, Hirsch E, Burke P, Quillen K. Low-dose recombinant activated factor VII in massively transfused trauma patients with coagulopathy. Transfusion 2007; 47:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/131\">",
"      Stein DM, Dutton RP, Kramer ME, et al. Recombinant factor VIIa: decreasing time to intervention in coagulopathic patients with severe traumatic brain injury. J Trauma 2008; 64:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/132\">",
"      Knudson MM, Cohen MJ, Reidy R, et al. Trauma, transfusions, and use of recombinant factor VIIa: A multicenter case registry report of 380 patients from the Western Trauma Association. J Am Coll Surg 2011; 212:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/133\">",
"      Pastores SM, Papadopoulos E, Voigt L, Halpern NA. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa. Chest 2003; 124:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/134\">",
"      Macdonald JA, Fraser JF, Foot CL, Tran K. Successful use of recombinant factor VII in massive hemoptysis due to community-acquired pneumonia. Chest 2006; 130:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/135\">",
"      Wheater MJ, Mead GM, Bhandari S, Fennell J. Recombinant factor VIIa in the management of pulmonary hemorrhage associated with metastatic choriocarcinoma. J Clin Oncol 2008; 26:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/136\">",
"      Shenoy A, Savani BN, Barrett AJ. Recombinant factor VIIa to treat diffuse alveolar hemorrhage following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/137\">",
"      Betensley AD, Yankaskas JR. Factor viia for alveolar hemorrhage in microscopic polyangiitis. Am J Respir Crit Care Med 2002; 166:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/138\">",
"      Witmer CM, Huang YS, Lynch K, et al. Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study. J Pediatr 2011; 158:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/139\">",
"      McQuilten ZK, Barnes C, Zatta A, et al. Off-label use of recombinant factor VIIa in pediatric patients. Pediatrics 2012; 129:e1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/140\">",
"      Guzzetta NA, Russell IA, Williams GD. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients. Anesth Analg 2012; 115:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/141\">",
"      Allen GA, Hoffman M, Roberts HR, Monroe DM 3rd. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. Can J Anaesth 2002; 49:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/142\">",
"      Allen GA, Wolberg AS, Oliver JA, et al. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004; 2:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/143\">",
"      Parameswaran R, Shapiro AD, Gill JC, et al. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/144\">",
"      Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/145\">",
"      O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/146\">",
"      Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/147\">",
"      Levy JH, Fingerhut A, Brott T, et al. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion 2006; 46:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/148\">",
"      Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/13/31962/abstract/149\">",
"      Thomas GO, Dutton RP, Hemlock B, et al. Thromboembolic complications associated with factor VIIa administration. J Trauma 2007; 62:564.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1341 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31962=[""].join("\n");
var outline_f31_13_31962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Conditions affecting rFVIIa activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Factor VIIa analog",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL UTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Approved indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hemophilia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Glanzmann thrombasthenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Off-label uses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22768015\">",
"      - Meta-analyses of off-label uses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Regulatory concerns and costs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OFF-LABEL EXPERIENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Congenital/acquired FVII deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Factor XI deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Inherited disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Excessive warfarin-associated bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Coagulopathy of liver dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Reduction of perioperative blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Managing post-traumatic hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Therapy with GPIIb/IIIa antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pulmonary hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24228136\">",
"      Off-label use in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DOSING AND LABORATORY MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SAFETY ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Thromboembolic events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Conclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Approved indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Off-label uses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1341\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1341|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/38/9836\" title=\"table 1\">",
"      Properties of coagulation factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=related_link\">",
"      Factor VIII and factor IX inhibitors in patients with hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/14/37097?source=related_link\">",
"      Factor XI deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1928?source=related_link\">",
"      General principles of the management of variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16730?source=related_link\">",
"      Rare (recessively inherited) coagulation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37945?source=related_link\">",
"      Refractoriness to platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32650?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24022?source=related_link\">",
"      Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10986?source=related_link\">",
"      The approach to the patient who refuses blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_13_31963="Giftedness definitions";
var content_f31_13_31963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used definitions for giftedness/outstanding talent",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        United States Department of Education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Children and youth with outstanding talent perform or show the potential for performing at remarkably high levels of accomplishment when compared with others of their age, experience, or environment. These children and youth exhibit high capability in intellectual, creative, and/or artistic areas, possess an unusual leadership capacity, or excel in specific academic fields. They require services or activities not ordinarily provided by the schools. Outstanding talents are present in children and youth from all cultural groups, across all economic strata, and in all areas of human endeavor.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The National Association for Gifted Children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Gifted individuals are those who demonstrate outstanding levels of aptitude (defined as an exceptional ability to reason and learn) or competence (documented performance or achievement in top 10 percent or rarer) in one or more domains. Domains include any structured area of activity with its own symbol system (eg, mathematics, music, language) and/or set of sensorimotor skills (eg, painting, dance, sports).\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      References:",
"     </p>",
"     <ol>",
"      <li>",
"       National Excellence: A case for developing America's talent. 1993. www.eric.ed.gov/PDFS/ED372580.pdf (Accessed on April 11, 2012).",
"      </li>",
"      <li>",
"       National Association for Gifted Children Position Paper: Redefining Giftedness for a New Century: Shifting the Paradigm. March 2010. Available at: www.nagc.org/index2.aspx?id=6404 (Accessed on April 11, 2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31963=[""].join("\n");
var outline_f31_13_31963=null;
var title_f31_13_31964="Pressure Ulcer Scale for Healing";
var content_f31_13_31964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pressure Ulcer Scale for Healing (PUSH)*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Assessments",
"       </td>",
"       <td class=\"subtitle1\">",
"        Instructions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Assign a subscore (cm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total the subscores",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"11\">",
"        Size (length x width)",
"       </td>",
"       <td rowspan=\"11\">",
"        Measure the greatest length and width using a centimeter ruler. Multiply the two measurements to obtain an estimate of surface area.",
"       </td>",
"       <td>",
"        0 - 0",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Subscore",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 - &lt;0.3",
"       </td>",
"       <td rowspan=\"10\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 - 0.3-0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 - 0.7-1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 - 1.1-2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 - 2.1-3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 - 3.1-4.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 - 4.1-8.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8 - 8.1-12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9 - 12.1-24.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 - &gt;24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Exudate",
"       </td>",
"       <td rowspan=\"4\">",
"        Estimate the amount of drainage after removal of the dressing.",
"       </td>",
"       <td>",
"        0 - None",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Subscore",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 - Light",
"       </td>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 - Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 - Heavy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Tissue type",
"       </td>",
"       <td rowspan=\"5\">",
"        Assess the presence of sloughing or necrosis",
"       </td>",
"       <td>",
"        0 - Closed",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Subscore",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 - Epithelial tissue",
"       </td>",
"       <td rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 - Granulation tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 - Slough",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 - Necrotic tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Add together all subscores =",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Total score",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in the score over time provide an indication of the healing process. The score goes down with improvement and increases with wound deterioration.",
"    <div class=\"footnotes\">",
"     * Version 3.0 National Pressure Ulcer Advisory Panel (www.npuap.org).",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: National Pressure Ulcer Advisory Panel. Version 3.0 Pressure Ulcer Scale for Healing (PUSH). Copyright &copy;1998 National Pressure Ulcer Advisory Panel.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31964=[""].join("\n");
var outline_f31_13_31964=null;
var title_f31_13_31965="Lyme seasonality";
var content_f31_13_31965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Confirmed Lyme disease cases by month of disease onset - United States, 2001 to 2010",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 338px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: United States Centers for Disease Control and Prevention. Lyme Disease Data. Available at:",
"     <a href=\"file://www.cdc.gov/lyme/stats/chartstables/casesbymonth.html\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.cdc.gov/lyme/stats/chartstables/casesbymonth.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31965=[""].join("\n");
var outline_f31_13_31965=null;
var title_f31_13_31966="Contents: Other bacterial infections";
var content_f31_13_31966=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Other bacterial infections",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Other bacterial infections",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Anaerobes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/34/41511\">",
"           Anaerobic bacteria: History and role in normal human flora",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/39/42617\">",
"           Anaerobic bacterial infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/36/37448\">",
"           Botulism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/23/43383\">",
"           Invasive Propionibacterium infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/39/34424\">",
"           Pathophysiology; clinical clues and recovery of organisms in anaerobic infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/11/7353\">",
"           Tetanus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bacillus anthracis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/3/7224\">",
"           Clinical manifestations and diagnosis of anthrax",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/10/39079\">",
"           Microbiology, pathogenesis, and epidemiology of anthrax",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/48/11016\">",
"           Prevention of anthrax",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/30/32232\">",
"           Treatment of anthrax",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bartonella",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/56/26503\">",
"           Bartonellosis: Oroya fever and verruga peruana",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/11/29879\">",
"           Basic biology of Bartonella species",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/46/36583\">",
"           Clinical features, diagnosis, and treatment of Bartonella quintana infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/2/18469\">",
"           Diagnosis, treatment, and prevention of Bartonella infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/63/8182\">",
"           Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/47/23289\">",
"           Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/2/37925\">",
"           Treatment of cat scratch disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Clostridium sordelli",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/25/1431\">",
"           Toxic shock syndrome due to Clostridium sordellii",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Leptospirosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/54/43879\">",
"           Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/31/4597\">",
"           Treatment and prevention of leptospirosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nocardia and actinomycosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/35/38452\">",
"           Abdominal actinomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/3/21559\">",
"           Cervicofacial actinomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/6/16489\">",
"           Clinical manifestations and diagnosis of nocardiosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/27/23991\">",
"           Microbiology, epidemiology, and pathogenesis of nocardiosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/55/29560\">",
"           Treatment of nocardiosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/36/6729\">",
"           Bacillus cereus and other non-anthracis Bacillus species",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/28/1478\">",
"           Erysipelothrix infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/62/28647\">",
"           Kikuchi's disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/28/31177\">",
"           Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/24/1413\">",
"           Rat bite fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/42/31401\">",
"           Zoonoses from cats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/24/29065\">",
"           Zoonoses from dogs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/22/26986\">",
"           Zoonoses from pets other than dogs and cats",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prosthetic device infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/57/34712\">",
"           Antimicrobial therapy of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/43/42678\">",
"           Breast implant infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/43/42680\">",
"           Clinical manifestations and diagnosis of prosthetic joint infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/4/35913\">",
"           Cochlear implant infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/40/2697\">",
"           Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/19/44345\">",
"           Infections involving cardiac implantable electronic devices",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/34/28198\">",
"           Prevention of prosthetic joint infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/32/3591\">",
"           Surgery for prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/19/6457\">",
"           Treatment of prosthetic joint infections",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Q fever",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/13/12502\">",
"           Clinical manifestations and diagnosis of Q fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/53/22357\">",
"           Microbiology and epidemiology of Q fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/57/15255\">",
"           Q fever endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/30/36323\">",
"           Treatment and prevention of Q fever",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rhodococcus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/22/18791\">",
"           Clinical features; diagnosis; therapy; and prevention of Rhodococcus equi infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/59/37814\">",
"           Microbiology; pathogenesis; and epidemiology of Rhodococcus equi infections",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-CF04E7A931-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f31_13_31966=[""].join("\n");
var outline_f31_13_31966=null;
var title_f31_13_31967="Anterior shoulder dislocation scapular Y view";
var content_f31_13_31967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior shoulder dislocation on a scapular Y view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The \"Y\" of this view is formed by the scapula's body, spine, and coracoid process. The glenoid normally falls in the center of the \"Y\" and is obscured by the humeral head. In this x-ray an anterior dislocation is present, and the humeral head appears&nbsp;anterior to the \"Y\".",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_13_31967=[""].join("\n");
var outline_f31_13_31967=null;
